

1 **Article type:** Review

2 **Prediction of oncogene mutation status in non-small cell lung cancer: A**  
3 **systematic review and meta-analysis with a special focus on artificial-**  
4 **intelligence-based methods**

5

6 Almudena Fuster-Matanzo<sup>†1</sup>, Alfonso Picó Peris<sup>†1</sup>, Fuensanta Bellvís Bataller<sup>1</sup>, Ana  
7 Jimenez-Pastor<sup>1</sup>, Glen J. Weiss<sup>2</sup>, Luis Martí-Bonmati<sup>3,4</sup>, Antonio Lázaro Sánchez<sup>5</sup>,  
8 Giuseppe L. Banna<sup>6</sup>, Alfredo Addeo<sup>7</sup>, Ángel Alberich-Bayarri<sup>1</sup>

9

10 <sup>1</sup>Quantitative Imaging Biomarkers in Medicine (Quibim), 46021 Valencia, Spain

11 <sup>2</sup>Quantitative Imaging Biomarkers in Medicine, Quibim, Boston, MA, USA, Boston,  
12 MA

13 <sup>3</sup>Grupo de Investigación Biomédica en Imagen, Instituto de Investigación Sanitaria La  
14 Fe, Avenida Fernando Abril Martorell, 106 Torre A planta 7, 46026, Valencia, Spain.

15 <sup>4</sup>Área Clínica de Imagen Médica, Área Clínica de Imagen Médica, Hospital Universitari  
16 i Politècnic La Fe, Avinguda Fernando Abril Martorell, 106 Torre E planta 0, 46026,  
17 València, Spain.

18 <sup>5</sup>

19 <sup>6</sup>Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth,  
20 PO6 3LY, UK; Faculty of Science and Health, School of Pharmacy and Biomedical  
21 Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK

22 <sup>7</sup>University Hospital Geneva, Geneva, Switzerland.

23 <sup>†</sup>These authors contributed equally to this work.

24

25 **Correspondence:**

26 Almudena Fuster-Matanzo

27 Quantitative Imaging Biomarkers in Medicine (Quibim),

28 EDIFICIO EUROPA, Av. d'Aragó, 30, Planta 13

29 46021 Valencia, Spain

30 Mail: [almudenafter@quibim.com](mailto:almudenafter@quibim.com)

31 Tel: +34 652124031

32

## 33 **ABSTRACT**

### 34 **Background**

35 In non-small cell lung cancer (NSCLC), alternative strategies to determine patient  
36 oncogene mutation status are essential to overcome some of the drawbacks associated  
37 with current methods. We aimed to review the use of radiomics alone or in combination  
38 with clinical data and to evaluate the performance of artificial intelligence (AI)-based  
39 models on the prediction of oncogene mutation status.

### 40 **Methods**

41 A PRISMA-compliant literature review was conducted. The Medline (via Pubmed),  
42 Embase, and Cochrane Library databases were searched for studies published through  
43 June 30, 2023 predicting oncogene mutation status in patients with NSCLC using  
44 radiomics. Independent meta-analyses evaluating the performance of AI-based models  
45 developed with radiomics features or with a combination of radiomics features plus  
46 clinical data for the prediction of different oncogenic driver mutations were performed.  
47 A meta-regression to analyze the influence of methodological/clinical factors was also  
48 conducted.

### 49 **Results**

50 Out of the 615 studies identified, 89 evaluating models for the prediction of epidermal  
51 growth factor-1 (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma  
52 virus (KRAS) mutations were included in the systematic review. A total of 38 met the  
53 inclusion criteria for the meta-analyses. The AI algorithms' sensitivity/false positive rate  
54 (FPR) in predicting EGFR, ALK, and KRAS mutations using radiomics-based models  
55 was 0.753 (95% CI 0.721–0.783)/0.346 (95% CI 0.305–0.390), 0.754 (95% CI 0.639–  
56 0.841)/ 0.225 (95% CI 0.163–0.302), and 0.744 (95% CI 0.605–0.846)/0.376 (95% CI  
57 0.274–0.491), respectively. A meta-analysis of combined models was only possible for  
58 EGFR mutation, revealing a sensitivity/FPR of 0.800 (95% CI 0.767–0.830)/0.335  
59 (95% CI 0.279–0.396). No statistically significant results were obtained in the meta-  
60 regression.

### 61 **Conclusions**

62 Radiomics-based models may represent valuable non-invasive tools for the  
63 determination of oncogene mutation status in NSCLC. Further investigation is required  
64 to analyze whether clinical data might boost their performance.

65 **Keywords:** radiomics, artificial intelligence, medical imaging, oncogene mutation  
66 status, non-small cell lung cancer.

67

## 68 INTRODUCTION

69 Lung cancer represents the most often diagnosed cancer in both women and men  
70 worldwide, ranking first and third, respectively, and remaining the leading cause of  
71 cancer death<sup>1</sup>. Non-small cell lung cancer (NSCLC), the most frequent histological  
72 subtype, accounts for 80%–85% of cases, being adenocarcinoma the most common  
73 subtype (40%–50% of cases). Adenocarcinoma can be further subdivided into distinct  
74 molecular subtypes<sup>2</sup>. Indeed, molecular subtyping has become highly relevant in the  
75 disease context, as genotype-driven therapy (“targeted therapy”) is nowadays the  
76 standard of care for a significant subgroup of patients with advanced and metastatic  
77 NSCLC<sup>3</sup>. However, traditional methods for determining the molecular genotype, as well  
78 as the possible emergence of drug resistance mutations during patient’s follow-up, entail  
79 invasive biopsies and genetic sequence testing, procedures with multiple number of  
80 associated drawbacks including high costs, sampling bias, lack of enough sample,  
81 turnaround time, and medical complications<sup>4-6</sup>. Importantly, the overall accessibility of  
82 molecular diagnostics and liquid biopsy may be limited for many patients<sup>7</sup>, highlighting  
83 the need to investigate complementary methods to characterize the oncogene mutation  
84 status of lesions.

85 Radiological imaging represents a potent non-invasive tool for lung cancer, from the  
86 screening, diagnosis and staging of the disease to the management, therapeutic  
87 planification and follow-up of both early- and advanced-stage cases<sup>8</sup>. Specifically,  
88 computed tomography (CT) remains the standard of care for lung cancer visualization,  
89 providing excellent morphological and textural information. In recent years, radiomics,  
90 the process of extracting and analyzing quantitative features from medical images to  
91 investigate potential connections with biology and clinical outcomes, has gained  
92 increasing attention for its applicability in several oncological diseases including lung  
93 cancer<sup>8</sup>. The application of artificial intelligence (AI) to imaging analyses has enabled  
94 important clinical needs to be met. This includes the prognostication of outcomes or the  
95 prediction of response to treatment, disease progression, or the mutational and  
96 molecular profiling of tumors<sup>9</sup>. In particular, the use of radiomics coupled with AI  
97 methods has demonstrated to be a promising non-invasive alternative tool for the  
98 prediction of oncogene mutation status in NSCLC<sup>8</sup>.

99 In this systematic review and meta-analysis we aimed to: 1) review the available  
100 scientific evidence on the use of imaging-based models and radiomics for the prediction

101 of the main targetable oncogenic driver alterations in NSCLC, including epidermal  
102 growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat  
103 sarcoma virus (KRAS); 2) analyze the overall performance of specifically, AI-based  
104 methods, for the prediction of oncogene mutation status; 3) evaluate whether the  
105 inclusion of clinical variables in the models improve their performance; 4) evaluate the  
106 impact of the available evidence from a clinical perspective.

## 107 **MATERIAL AND METHODS**

108 This systematic review was conducted in accordance with the Preferred Reporting Items  
109 for Systematic Reviews and Meta-Analysis (PRISMA) guidelines<sup>10</sup>. The review was  
110 registered on PROSPERO before initiation (registration no. CRD42022349809).

### 111 **Search strategy**

112 A systematic search for eligible publications published through 30 June 2023 was per-  
113 formed in Medline (via Pubmed), Cochrane Library and EMBASE databases using the  
114 keywords “Radiomics”, “NSCLC” and “Mutational status”. Further details on the  
115 search terms used in each database are provided in **Supplementary Table S1**. There  
116 were no limitations on the publishing year, participant age, or nationality. The search  
117 was exclusively limited to English-language publications.

### 118 **Study selection**

119 Literature search and study selection were independently performed by two reviewers  
120 (A.F.M. and A.L.S.). To find relevant publications, they reviewed the titles and  
121 abstracts. Studies that satisfied the inclusion criteria were then manually assessed for  
122 eligibility by full-text screening. Covidence systematic review software (Veritas Health  
123 Innovation, Melbourne, Australia. Available at [www.covidence.org](http://www.covidence.org)) was used as a  
124 screening and data extraction tool.

### 125 *Inclusion criteria*

126 Papers were included in the qualitative synthesis (systematic review) if meeting the  
127 following inclusion criteria based on Patient, Index test, Comparator, Reference test,  
128 Diagnosis of reference (PIRD) questions: 1) being focused on the ability of radiomics to  
129 predict oncogene mutation status in NSCLC; 2) radiomics features were extracted from  
130 CT or from F-18 fluoro-deoxy-glucose (FDG)/CT scans; 3) a full text was available; 4)  
131 were written in English.

132 *Exclusion criteria*

133 Papers describing studies conducted using MRI scans (not the standard of care for  
134 NSCLC patients) or performed in phantom or animal models, or published as case  
135 reports, editorials, reviews, poster presentations, letters, editorials, or meeting abstracts  
136 were excluded. Papers not on the field of interest were also excluded.

137 For the quantitative synthesis (meta-analysis), the following additional exclusion  
138 criteria were applied: 1) oncogene mutation status was not the primary objective of the  
139 paper; 2) were focused on specific mutation subtypes; 3) did not apply AI-based  
140 methodologies; 4) developed simultaneous detection models or discriminant models; 5)  
141 sensitivity or specificity metrics were not available and could not be calculated; 6) were  
142 not comparable with the other articles included (model was developed based on intra-  
143 and extra-tumor derived radiomics features); 7) only included models developed with a  
144 combination of quantitative features extracted from PET/CT or from PET images  
145 (strictly adhering to a clinical perspective, PET scanning equipment is not always  
146 available and CT remains the standard of care for NSCLC patients); 8) did not reach a  
147 sufficient quality score according to the quality assessment (described below).

148 *Quality assessment*

149 The methodological quality of each study for its possible inclusion in the quantitative  
150 assessment was evaluated by using the Checklist for Artificial Intelligence in Medical  
151 Imaging (CLAIM)<sup>11</sup>. Classification, image reconstruction, text analysis, and workflow  
152 optimization are some of the applications of AI in medical imaging that are addressed  
153 by CLAIM, which is modeled after the Standards for Reporting of Diagnostic Accuracy  
154 Studies (STARD) guideline<sup>12-15</sup>. CLAIM checklist consists of 42 items divided into the  
155 conventional sections included in peer-reviewed scientific articles: title or abstract (1  
156 item), abstract (1 item), introduction (2 items), methods (28 items subdivided into study  
157 design [2 items], data [7 items], ground truth [5 items], data partitions [3 items], model [3  
158 items], training [3 items] and evaluation [5 items]), results (5 items subdivided into  
159 data [2 items] and model performance [3 items]), discussion (2 items) and other  
160 information (3 items). The CLAIM guideline offers a roadmap for writers and reviewers  
161 with the intention of fostering clear, open, and verifiable scientific discourse on the use  
162 of AI in medical imaging<sup>11</sup>.

163 For our quality assessment, a score was calculated for each paper ([total score, 42 -  
164 number of “not applicable” fields in each case]). A cut-off value of at least half of the  
165 total score after removing the “not applicable” items was established for the inclusion in  
166 the quantitative analysis. Therefore, this cut-off value varied for each study depending  
167 on the number of items that were applicable from among the 42 total items included in  
168 the CLAIM checklist (e.g., a cut-off value of 19 was established for those studies in  
169 which only 38 items of the checklist were applicable). **See Supplementary Table S2.**  
170 The assessment of the rigor, quality, and generalizability of the work of all enrolled  
171 studies was performed by three reviewers (A.J.P., F.B.B. and A.P.P.).

## 172 **Data extraction**

173 Data extracted included the following: (1) study details: first author, publication year,  
174 research questions, study design; (2) patient details: the source of data acquisition  
175 (single-center/multicenter), sample size, smoking history, age, sex, TNM staging,  
176 treatment status (naïve or any treatment received prior image acquisition), histological  
177 subtype; (3) imaging details: imaging modality, plain or contrast CT; (4) oncogene  
178 mutation status-related information: type of mutation, specific subtype of mutation (if  
179 available), sequencing method; sequencing kit (5) radiomics details: segmentation  
180 software, type of segmentation (manual, automatic, or semi-automatic), radiomics  
181 feature extraction software, number of imaging features extracted, number and name of  
182 radiomics features included in final models, features selection methods, type of models  
183 constructed (machine learning [ML], deep learning [DL], classical statistical model),  
184 final classifier used in machine learning models, clinical variables included in the  
185 models (if applicable), and models performance. Two independent reviewers (A.F.M.  
186 and A.L.S.) completed the initial screening and extracted data from all included studies.

## 187 **Data analysis**

188 For studies including models based on features extracted from different imaging  
189 modalities, only those based on CT scans were included in the quantitative analysis. A  
190 bivariate analysis of sensitivity and specificity as proposed by Reitsma et al.<sup>16</sup> was  
191 chosen to perform the meta-analyses. This method has the distinct advantage of  
192 preserving the two-dimensional nature of the underlying data. It can also produce  
193 summary estimates of sensitivity and specificity (false positive rate [FPR, 1-  
194 specificity]), recognizing any possible correlation between these two measures. The



195 method uses a random effect approach in which the values of the sensitivity and FPR  
196 estimates are obtained with restricted maximum likelihood. As a complement to the  
197 bivariate approach, the summary receiver operating characteristic (sROC) was  
198 calculated by converting each pair of sensitivity and specificity into a single measure of  
199 accuracy, the diagnostic odds ratio (DOR).

200 The analyses were carried out by reproducing the confusion matrices of each model  
201 presented in the studies, the number of cases and the prevalence of oncogene mutant  
202 positive cases. All calculations were performed on the basis of validation cohorts for  
203 studies applying a training/validation split method, or on the basis of the total sample  
204 when cross-validation was the validation strategy. To ensure homogeneity, calculations  
205 were conducted based on internal validation cohort data when external validation was  
206 also performed (minority of the cases).

207 Finally, a meta-regression analysis was performed to measure the possible influence of  
208 the following predictors: (1) average age of the cases, (2) manual segmentation vs semi-  
209 automatic segmentation vs both procedures (no studies including automatic  
210 segmentation approaches met the inclusion criteria for the quantitative analysis), (3)  
211 whether the model included only radiomics features or was combined with clinical  
212 variables, and (4) whether the model was classified as ML or DL. The heterogeneity in  
213 the description of the clinical variables included in the models prevented the inclusion  
214 of additional predictors of greatest clinical interest. Only the best model from each  
215 study according to its DOR was selected. When the mean/median age was not available  
216 due to the heterogeneity among studies when presenting descriptive results, it was  
217 inferred from the information obtained. Thus, mean and median values were indistinctly  
218 considered; when both values were provided, an average of both was calculated. If  
219 mean values were absent, median values were considered and viceversa. If both values  
220 were absent from the validation cohort, mean/median age from the total cohort was  
221 considered. When this information was not available either, the study was not included  
222 in the meta-regression.

223 All the analyses were performed using R Statistical Software v4.2.2 and the packages  
224 mada and tidyverse.

## 225 **RESULTS**

226 In total 615 articles were obtained according to the search strategy (**Figure 1**). After de-  
227 duplication, 397 studies were obtained and screened. According to the inclusion and  
228 exclusion criteria, 89 studies were included in the qualitative analysis (systematic  
229 review), all of them developing models for the prediction of EGFR, ALK, and/or  
230 KRAS. Out of those, 38 were found eligible for the quantitative part of the study (meta-  
231 analyses). As detailed in **Supplementary Table S2**, all papers passed this quality check  
232 and were therefore included.

### 233 **Qualitative analysis (systematic review)**

#### 234 *Methodological characteristics of the studies*

235 The methodological characteristics of the studies are summarized in **Table 1**. Most of  
236 the studies ( $n = 69/ 89$ ) applied exclusively ML algorithms, while this methodology was  
237 also used to build comparator models in 10 articles in which DL techniques were the  
238 main methodological approach followed. Only three studies exclusively applied DL  
239 algorithms, while classical statistical models were used in seven publications. Among  
240 the 79 articles applying ML techniques, the most common classifier used was logistic  
241 regression ( $n = 38$ ), followed by support vector machine ( $n = 35$ ) and by random forest  
242 ( $n = 29$ ). In terms of partitioning strategy, training-validation split was the most frequent  
243 technique ( $n = 71$ ). External validation was only performed in a small set of studies  
244 ( $n = 9$ ). Regarding imaging techniques, CT was the most frequently used modality  
245 ( $n = 61$ ), followed by PET/CT ( $n = 22$ ) and by PET alone ( $n = 4$ ). Additionally, in one  
246 study<sup>17</sup> PET/CT scans and contrast-enhanced CT images independently acquired were  
247 collected, while in another study<sup>18</sup>, PET/CT, CT, and contrast-enhanced diagnostic  
248 quality (CTD) images were used. Of the 61 studies conducted with CT scans, 39  
249 included non-contrast-enhanced images, 18 contrast-enhanced images, in two contrast-  
250 related information was not specified and in two both contrast- and non-contrast-  
251 enhanced scans were included. Regarding tumor segmentation, a manual approach was  
252 followed in 48 studies, and automatic and semi-automatic segmentations were applied  
253 in two and 31 studies, respectively; three studies applied both methodologies (for  
254 verification or a different approach according to the imaging modality used) and five  
255 studies did not specify the method utilized for tumor segmentation.

#### 256 *Clinical characteristics of the studies*

257 The 89 studies evaluated in the qualitative synthesis included a total of 32,084 patients  
258 with NSCLC. Although most of the studies included >200 patients, in 42 publications,  
259 the sample size did not reach this figure and in 11 studies sample size was even lower  
260 than 100. All studies were retrospective and mostly unicentric ( $n = 72$ ); the number of  
261 participant centers was not specified in one study<sup>19</sup>. In general, basic clinical and  
262 demographic information collected included sex, age, smoking status, TNM stage,  
263 histology, and treatment status at the moment of image acquisition, although this  
264 information was not available in 13, 9, 22, 34, 22 and 24 studies out of the 89 assessed,  
265 respectively. The clinical characteristics of the patients included in the 89 studies are  
266 depicted in **Table 2**. The median [range]/ mean  $\pm$  standard deviation (SD) age of  
267 patients was 61.78 [59–64.17] years and  $61.71 \pm 3.64$  years, respectively. In terms of  
268 sex, the total population was balanced, with 13,574 females and 14,066 males. The  
269 smoking history was available for 23,200 patients, and many were non-smokers  
270 ( $n = 12,813$ ); while smoking history was unknown for 1,146 patients. Out of the 55  
271 studies detailing information about the TNM stage, the majority of them ( $n = 40$ )  
272 included information about the four stages (I-IV), either provided per group or grouped  
273 in stages I-II and stages III-IV. Among the 15 studies that did not include patients of all  
274 stages, two studies included only early stage patients (stages I and II)<sup>20, 21</sup>, two included  
275 patients stage II-IV<sup>22, 23</sup>, six included only patients of stages III and IV<sup>24-29</sup> (three of  
276 them with a majority of stage IV patients<sup>24, 27, 29</sup>), and five included patients of stages I-  
277 III without including the most advanced stage<sup>19, 30-33</sup>. A total of 65 studies included  
278 patients with adenocarcinoma: 43 exclusively including this histology subtype and 22  
279 including other NSCLC histology types as well. Finally, in most of the cases ( $n = 65$ ),  
280 images were acquired before patients received any treatment, with two studies also  
281 including post-treatment images<sup>34, 35</sup>. In 24 studies, no information on treatment was  
282 detailed, although in some of them image acquisition before surgery<sup>31, 36-41</sup>, before  
283 polymerase chain reaction (PCR)<sup>42</sup>, or before pathological diagnosis<sup>43</sup> was detailed as  
284 an inclusion criterion. In five studies<sup>19, 44-47</sup>, authors specify that patients had not  
285 received radiotherapy or chemotherapy, but no information on targeted therapy was  
286 provided. Finally, only one study<sup>48</sup> out of the 89 included in the systematic review,  
287 which did not meet the inclusion criteria to be considered for the meta-analysis,  
288 included patients who had received treatment with tyrosine kinase inhibitors (TKIs).

## 289 **Quantitative analysis (meta-analysis)**

290 A total of 38 studies met the inclusion criteria for the quantitative assessment  
291 ( $n = 17,066$  patients). Three main different meta-analyses including radiomics-based  
292 models were conducted: 1) a meta-analysis including studies focused on the detection of  
293 EGFR ( $n = 34$  studies)<sup>17, 25-28, 32, 33, 36, 38, 39, 46, 49-71</sup>; 2) a meta-analysis including studies  
294 focused on the detection of ALK ( $n = 3$  studies)<sup>72-74</sup>; 3) a meta-analysis including  
295 studies focused on the detection of KRAS ( $n = 4$  studies)<sup>47, 50, 54, 62</sup>. In three studies,  
296 authors developed models for the detection of both EGFR and KRAS<sup>50, 54, 62</sup>.  
297 Furthermore, a separate meta-analysis was conducted for combined models (radiomics  
298 features + clinical variables) for the prediction of EGFR (not enough studies for ALK or  
299 KRAS mutations). Studies included in all the meta-analyses conducted are summarized  
300 in **Supplementary Table S3**. Details on the radiomics features included in the EGFR,  
301 ALK, and KRAS models are summarized in **Supplementary Table S4**,  
302 **Supplementary Table S5** and **Supplementary Table S6**, respectively. In terms of  
303 radiomics variables, models grouped different combinations of first order, shape, gray  
304 level co-occurrence matrix (GLCM), gray level size zone matrix (GLSZM), gray level  
305 run length matrix (GLRLM), neighboring gray tone difference matrix (NGTDM), and  
306 gray level dependence matrix (GLDM) features. Clinical data included sex, smoking  
307 history, and/or histological type in the majority of studies.

### 308 *EGFR*

309 Results of the meta-analysis focused on models built with radiomics features are  
310 summarized in **Figure 2**. Note that this meta-analysis also included a study<sup>50</sup> in which  
311 predictions were based on features extracted by a multi-channel and multi-task deep  
312 learning model with the ability to simultaneously detect EGFR and KRAS oncogene  
313 mutations; and consequently, did not include radiomics features (only single-task results  
314 for the independent prediction of EGFR and KRAS were considered for the quantitative  
315 analysis). A hierarchical sROC curve was plotted for the included 24 studies<sup>17, 25, 27, 32,</sup>  
316 <sup>36, 39, 46, 49-51, 54, 55, 57-60, 62, 64-66, 68-71</sup> that evaluate the performance of AI algorithms in  
317 predicting EGFR mutation status in NSCLC (**Supplementary Figure S1**). Eight studies  
318 assessed more than one model<sup>32, 36, 39, 50, 59, 60, 65, 70</sup>. As observed, radiomics-based models  
319 exhibited high diagnostic performance in predicting EGFR mutation status with an  
320 overall AUC of 0.766. The AI algorithms' sensitivity in determining the EGFR mutation

321 status varied from 0.362 to 0.948, resulting in an estimate of 0.753 (95% CI 0.721–  
322 0.783). The FPR of these algorithms ranged from 0.022 to 0.761, with a estimate of  
323 0.346 (95% CI 0.305–0.390). Detecting a positive case for EGFR mutation was almost  
324 six times more likely than not detecting it (DOR = 5.70 [95% CI 4.74–6.81]).

325 The effect of adding clinical variables to radiomics models or to models including both  
326 radiomics and deep features<sup>65</sup> (models including clinical data and radiomic or deep  
327 features referred in this work as combined models) in the prediction of EGFR mutation  
328 was also analyzed. This meta-analysis included 23 studies<sup>25, 26, 28, 32, 33, 38, 39, 46, 51-53, 56-58,</sup>  
329 <sup>61-69</sup>, of which four of them developed more than one model<sup>32, 39, 56, 67</sup>. Results are  
330 depicted in **Figure 3** and sROC curve in **Supplementary Figure S1**. Overall, the  
331 performance of combined models slightly improved compared to radiomics models,  
332 with an AUC of 0.811 and a sensitivity of 0.800 (95% CI 0.767–0.830; model’s  
333 sensitivity ranging from 0.523 to 0.944). The FPR resulted similar with a value of 0.335  
334 (95% CI 0.279–0.396; model’s FPR ranging from 0.167 to 0.760.). Detecting a positive  
335 case for EGFR mutation with combined models was more than eight times more likely  
336 than not detecting it (DOR = 8.35 [95% CI 6.77–10.20]).

### 337 *ALK*

338 The meta-analysis focused on radiomics-based models included three studies<sup>72-74</sup>, one of  
339 which developed two different models, one based on pre-contrast images and another  
340 one on post-contrast images<sup>73</sup>. An overall AUC of 0.831 was obtained for the prediction  
341 of ALK aberration, with a sensitivity ranging from 0.682 to 0.825, resulting in an  
342 estimate of 0.754 (95% CI 0.639–0.841). The FPR of these algorithms ranged from  
343 0.167 to 0.277, with an estimate of 0.225 (95% CI 0.163–0.302). Detecting a positive  
344 case for ALK aberration was 11 times more likely than not detecting it (DOR = 5.70  
345 [95% CI 5.83–19.10]) (**Figure 4** and **Supplementary Figure S2**). Given the lack of  
346 enough studies developing combined models, a meta-analysis to assess the effects of  
347 adding clinical variables in the prediction of ALK aberration was not possible. The only  
348 study<sup>74</sup> that developed a model including age, sex, smoking history, smoking index,  
349 clinical stage, distal metastasis and pathological invasiveness of the tumor in  
350 combination with conventional CT features and different first order, GLCM, GLSZM,  
351 and GLRL radiomics features demonstrated increased performance in predicting ALK  
352 aberration of the combined model vs the radiomics-based model, but only in the

353 primary cohort (AUC , 0.83–0.88,  $p = 0.01$ ), not in the testing cohort (AUC , 0.80–0.88,  
354  $p = 0.29$ ).

355 *KRAS*

356 Four studies met the inclusion criteria for the meta-analysis assessing models for KRAS  
357 mutation prediction<sup>47, 50, 54, 62</sup>, among which, three of them also developed models for  
358 EGFR mutation prediction<sup>50, 54, 62</sup>. KRAS/EGFR models were independently built  
359 except in one study, in which a multi-channel multi-task DL model for the prediction of  
360 both KRAS and EGFR mutations was developed<sup>50</sup>. However, and according to the  
361 inclusion criteria, only single-task metrics were considered for the quantitative analysis  
362 despite the multi-channel version displayed the highest performance for the  
363 simultaneous detection of both oncogenic driver mutations. Results of the meta-analysis  
364 evaluating radiomics-based models are shown in **Figure 4** and **Supplementary Figure**  
365 **S3**. KRAS mutation was predicted with an overall AUC of 0.732 and a sensitivity of  
366 0.744 (95% CI 0.605–0.846; model’s sensitivity ranging from 0.641 to 0.875. The FPR  
367 was 0.376 (95% CI 0.274–0.491; model’s FPR ranging from 0.259 to 0.468). Detecting  
368 a positive case for KRAS mutation with radiomics-based models was more than five  
369 times more likely than not detecting it (DOR = 8.35 [95% CI 1.98–11.70]). Like ALK,  
370 the lack of enough KRAS studies made it impossible to perform a meta-analysis  
371 analyzing combined models. Only Ríos Velázquez et al.<sup>62</sup> built a model including age,  
372 sex, smoking status, race, and clinical stage together with radiomics features that  
373 performed similar to the radiomics model (AUC = 0.69 [95% CI: 0.63– 0.75] vs  
374 AUC = 0.63 [95% CI: 0.57– 0.69]) and worse than a model developed only with clinical  
375 data AUC = 0.75 [95% CI: 0.69–0.80].

376 *Meta-regression and subgroup analysis*

377 The possible effects of different predictors on the predictive performance of the models  
378 was evaluated for EGFR mutation (not enough studies were available for ALK or  
379 KRAS mutations). Neither age, nor the use of contrast, nor the type of segmentation  
380 (manual/semi-automatic/automatic), nor the model (radiomics/combined), nor the AI  
381 methodology (machine learning/deep learning), yielded statistically significant results  
382 (**Supplementary Table S7**).

## 383 **DISCUSSION**

384 At present, molecular testing performed on biopsied tissue remains the gold standard for  
385 diagnosis and genotyping in advanced NSCLC<sup>75, 76</sup>. However, given the associated  
386 limitations and inconveniences, such as the lack of enough tissue for successful  
387 testing<sup>77, 78</sup>, or the long turnaround times<sup>76</sup>, there is a need to validate and incorporate  
388 new procedures into routine clinical practice. In recent years, liquid biopsy has emerged  
389 as a promising alternative in NSCLC, especially in clinical scenarios<sup>78</sup>. Likewise,  
390 radiomics have shown encouraging results in prognosis and prediction in this setting<sup>79</sup>.  
391 In general, both methodologies possess great potential, since they are both simple,  
392 straightforward to do, and repeatable at patient follow-up visits, which makes it possible  
393 to gather important data about the type of tumor, its aggressiveness, its progression, and  
394 its response to therapy<sup>80</sup>. Radiomics has the additional advantage of only requiring  
395 medical images and capturing patient-level and tissue-level heterogeneity, such as CT  
396 scans in lung cancer, that are usually acquired as part of the patient's standard journey,  
397 representing an affordable methodology both in terms of resources and costs. It is  
398 important that new techniques are properly validated to facilitate their standardization,  
399 prior to incorporation into the routine clinical workflow.

400 To our knowledge, this is the first systematic review and meta-analysis that analyzes the  
401 performance and applicability of different imaging-based models for the prediction of  
402 three of the most common oncogene mutations—EGFR, ALK and KRAS—in NSCLC  
403 from a clinical perspective and with a special focus on AI methodologies. So far, results  
404 were only available for EGFR studies and did not take clinical aspects into account<sup>81</sup>.  
405 Thus, the results of our different meta-analyses demonstrate that AI-based models  
406 developed with CT-derived radiomics features showed good performance in predicting  
407 EGFR, ALK, and KRAS mutations with a sensitivity of 0.753 [95% CI (0.721–0.783)],  
408 0.754 [95% CI (0.639–0.841)] and 0.744 [95% CI (0.605–0.846)], respectively.  
409 Whether the inclusion of clinical variables increase models' performance cannot be  
410 concluded from our results, although we believe that increasing the number of studies  
411 would probably confirm the trends observed in our quantitative analysis of EGFR  
412 mutation.

413 Our outcomes point to radiomics as a candidate screening tool for oncogene mutation  
414 status determination. We especially focused on CT-based models, aiming to obtain

415 conclusions as applicable as possible to the standard clinical workflow since CT  
416 remains the most utilized imaging tool in NSCLC<sup>82</sup>. From our work, we conclude that  
417 in addition to additional validation of our findings that future studies should be  
418 conducted that consider the following important aspects. Firstly, a minimum sample size  
419 should be guaranteed to ensure the reliability of the results obtained with AI-based  
420 models<sup>83, 84</sup>. In both our systematic review and meta-analyses, more than half of the  
421 studies were conducted in >200 patients ( $n = 46/89$  and  $n = 23/38$  [ $n = 20/34$  for EGFR,  
422  $n = 2/3$  for ALK and  $n = 3/4$  for KRAS]), but still a sizable number had small sample  
423 sizes, which definitely limited the relevance of their conclusions. Multicentric designs  
424 would be also desirable to get more solid conclusions, an approach that few studies  
425 followed ( $n = 16/89$  in the systematic review and  $n = 10/39$  in the meta-analysis  
426 [ $n = 10/34$  for EGFR,  $n = 0/3$  for ALK and  $n = 3/4$  for KRAS]). Secondly, including  
427 independent cohorts for external validations would reinforce the results, leading to more  
428 robust and reproducible models. Out of the 89 studies included in the qualitative  
429 analysis, only 9 used external cohorts for validation<sup>43, 46, 60, 63, 67, 68, 85-87</sup>, of which five  
430 were included in the EGFR meta-analysis<sup>46, 60, 63, 67, 68</sup>. Finally, it is important that  
431 patient populations reflect clinical practice. Thus, considering the potential applicability  
432 of the models for diagnostic purposes, studies should be conducted in treatment naïve  
433 populations to avoid possible therapy-related confounding effects, an inclusion criterion  
434 mostly applied in the studies evaluated in this work, but still missing in some of them.  
435 Additionally, studies should be carried out preferably in stage III-IV NSCLC patients  
436 (especially in those at stage IV, for whom clinical guidelines recommend molecular  
437 testing<sup>75, 76</sup>). As demonstrated in this work, most of the studies published so far do not  
438 provide information on TNM stage or include patients from all stages. Despite the  
439 heterogeneity of the studies evaluated, we believe that the evidence provided is enough  
440 as to demonstrate the potential of radiomics in oncogene mutation status determination.  
441 Thus, AI-based models using radiomics extracted from CT scans could be effective non-  
442 invasive screening tools to detect targetable driver mutations in NSCLC with good  
443 sensitivity and moderate specificity. These tools would not be intended to replace gold  
444 standard techniques, such as PCR or next-generation sequencing, but to allow for the  
445 potential earlier identification of ideal candidates to be genetically tested, saving time,  
446 costs, and samples. Consequently, a high sensitivity would ensure the identification of  
447 oncogene mutation positive patients for whom laboratory-based testing would be  
448 subsequently confirmed.



449 When the influence of different factors on the prediction of EGFR mutation was  
450 evaluated, no statistically significant results were obtained, probably due to the limited  
451 number of studies included and the presence of missing data. However, some of those  
452 factors might play an essential role and should be considered when developing accurate  
453 models to be potentially implemented into clinical practice. Indeed, some of the studies  
454 included in our qualitative analysis analyzed the impact of different methodological  
455 aspects on the performance of the models. For example, Huang et al.<sup>35</sup> demonstrated  
456 that interobserver variability in tumor segmentation affects the use of radiomics to  
457 predict oncogene mutation status, which suggests that automatic or semi-automatic  
458 models might be more suitable. In the study by Shiri et al.<sup>88</sup>, the application to  
459 radiomics features of ComBat harmonization improved the performance of the models  
460 toward more successful prediction of EGFR and KRAS mutations. Likewise, other  
461 authors have pointed to the impact of the experimental settings on the robustness of  
462 radiomics features<sup>89</sup>, or the influence of CT slice thickness on the predictive  
463 performance of radiomics-based models<sup>31</sup>. It is also worth mentioning the relevance of  
464 using a particular AI methodology. Although we found no differences in the EGFR  
465 mutation predictive performance between ML and DL methods, most likely due to the  
466 limited number of available DL-based studies, the latter might offer some advantages  
467 over the former. Thus, while in radiomics analysis a process of lesion segmentation and  
468 subsequent feature extraction is required, which introduces certain degree of variability  
469 and can be a high time-consuming task, DL models only required a bounding box of the  
470 lesion, greatly reducing this effect. On the other hand, DL models, and in particular end-  
471 to-end convolutional neural network (CNN) models, such those developed in most of  
472 the DL studies included in our work<sup>37, 42, 43, 50, 58, 68, 85, 86, 90, 91</sup>, are generally more  
473 complex in terms of the number of parameters, allowing to solve more complicated  
474 problems than traditional ML models. Considering available evidence, it seems  
475 reasonable to think that methodologic approaches should be carefully revised when  
476 validation studies are designed and conducted.

477 Our study has also some limitations, mainly derived from the limitations of the  
478 publications included. Thus, it is based on retrospective studies displaying great  
479 heterogeneity in terms of methodology and patient clinical characteristics, which clearly  
480 hamper the impact of our conclusions. Additionally, the limited available evidence for  
481 ALK and KRAS mutations, makes it difficult to draw solid conclusions. Despite this,

482 our work gathers the most up-to-date and complete evidence (all models developed in  
483 each of the studies were analyzed) on imaging-based models for the prediction of three  
484 of the most important oncogene mutations in NSCLC, following a clinical approach and  
485 a special focus on AI models. Our exhaustive review and meta-analyses are intended to  
486 provide solid evidence for future research in the field.

487 In conclusion, radiomics-based models offer a useful and non-invasive method for  
488 determining the status of EGFR mutations in NSCLC and seem to retain similar  
489 predictive value for ALK and KRAS mutations. Additionally, although the inclusion of  
490 clinical variables tends to increase the performance of the models, further validation is  
491 required.

## 492 **ACKNOWLEDGEMENTS**

493

## 494 **CONFLICTS OF INTEREST**

495 GJW reports personal fees from Quibim related to this work. He is a former employee  
496 of SOTIO Biotech Inc., and reports personal fees from Imaging Endpoints II,  
497 MiRanostics Consulting, Gossamer Bio, International Genomics Consortium, Angiex,  
498 Genomic Health, Oncacare, Rafael Pharmaceuticals, Roche, Immunocore, Kymera, and  
499 SPARC-all outside this submitted work; has ownership interest in MiRanostics  
500 Consulting, Exact Sciences, Moderna, Agenus, Aurinia Pharmaceuticals, and  
501 Circulogene-outside the submitted work; and has issued patents- all outside the  
502 submitted work. The remaining authors declare no conflicts of interest.

## 503 **FUNDING**

504

## 505 **REFERENCES**

- 506 1 Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN  
507 estimates of incidence and mortality worldwide for 36 Cancers in 185 countries.  
508 *CA Cancer J Clin.* 2021; 71(3): 209-249.
- 509 2 Osmani L, Askin F, Gabrielson E et al. Current WHO guidelines and the critical  
510 role of immunohistochemical markers in the subclassification of non-small cell  
511 lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy.  
512 *Semin Cancer Biol.* 2018; 52(Pt 1): 103-109.

- 513 3 König D, Savic Prince S, Rothschild SI. Targeted therapy in advanced and  
514 metastatic non-small cell lung cancer. An update on treatment of the most  
515 important actionable oncogenic driver alterations. *Cancers (Basel)*. 2021; 13(4).
- 516 4 Chiu YW, Kao YH, Simoff MJ et al. Costs of biopsy and complications in  
517 patients with lung cancer. *Clinicoecon Outcomes Res*. 2021; 13: 191-200.
- 518 5 Manicone M, Poggiana C, Facchinetti A et al. Critical issues in the clinical  
519 application of liquid biopsy in non-small cell lung cancer. *J Thorac Dis*. 2017;  
520 9(Suppl 13): S1346-s1358.
- 521 6 Young M SR. Percutaneous lung lesion biopsy. [Updated 2023 Jun 19].  
522 *StatPearls [Internet]*. . Treasure Island (FL): StatPearls Publishing.
- 523 7 Di Capua D, Bracken-Clarke D, Ronan K et al. The liquid biopsy for lung  
524 cancer: state of the art, limitations and future developments. *Cancers (Basel)*.  
525 2021; 13(16).
- 526 8 Wu G, Jochems A, Refaee T et al. Structural and functional radiomics for lung  
527 cancer. *Eur J Nucl Med Mol Imaging*. 2021; 48(12): 3961-3974.
- 528 9 Bera K, Braman N, Gupta A et al. Predicting cancer outcomes with radiomics  
529 and artificial intelligence in radiology. *Nat Rev Clin Oncol*. 2022; 19(2): 132-  
530 146.
- 531 10 Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an  
532 updated guideline for reporting systematic reviews. *BMJ*. 2021; 372: n71.
- 533 11 Mongan J, Moy L, Kahn CE. Checklist for artificial intelligence in medical  
534 imaging (CLAIM): a guide for authors and reviewers. *Radiol Artif Intell*. 2020;  
535 2(2): e200029.
- 536 12 Bossuyt PM, Reitsma JB. The STARD initiative. *Lancet*. 2003; 361(9351): 71.
- 537 13 Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate  
538 reporting of studies of diagnostic accuracy: the STARD initiative. *Radiology*.  
539 2003; 226(1): 24-28.
- 540 14 Bossuyt PM, Reitsma JB, Bruns DE et al. STARD 2015: an updated list of  
541 essential items for reporting diagnostic accuracy studies. *Radiology*. 2015;  
542 277(3): 826-832.
- 543 15 Cohen JF, Korevaar DA, Altman DG et al. STARD 2015 guidelines for reporting  
544 diagnostic accuracy studies: explanation and elaboration. *BMJ Open*. 2016;  
545 6(11): e012799.
- 546 16 Reitsma JB, Glas AS, Rutjes AW et al. Bivariate analysis of sensitivity and  
547 specificity produces informative summary measures in diagnostic reviews. *J  
548 Clin Epidemiol*. 2005; 58(10): 982-990.
- 549 17 Nair JKR, Saeed UA, McDougall CC et al. Radiogenomic models using  
550 machine learning techniques to predict EGFR mutations in non-small cell lung  
551 cancer. *Can Assoc Radiol J*. 2021; 72(1): 109-119.
- 552 18 Shiri I, Maleki H, Hajianfar G et al. Next-generation radiogenomics sequencing  
553 for prediction of EGFR and KRAS mutation status in NSCLC patients using

- 554 multimodal imaging and machine learning algorithms. *Mol Imaging Biol.* 2020;  
555 22(4): 1132-1148.
- 556 19 Dang Y, Wang R, Qian K et al. Clinical and radiological predictors of epidermal  
557 growth factor receptor mutation in nonsmall cell lung cancer. *J Appl Clin Med*  
558 *Phys.* 2021; 22(1): 271-280.
- 559 20 Omura K, Murakami Y, Hashimoto K et al. Detection of EGFR mutations in  
560 early-stage lung adenocarcinoma by machine learning-based radiomics. *Transl*  
561 *Cancer Res.* 2023; 12(4): 837-847.
- 562 21 Wang X, Kong C, Xu W et al. Decoding tumor mutation burden and driver  
563 mutations in early stage lung adenocarcinoma using CT-based radiomics  
564 signature. *Thorac Cancer.* 2019; 10(10): 1904-1912.
- 565 22 Liu Q, Sun D, Li N et al. Predicting EGFR mutation subtypes in lung  
566 adenocarcinoma using (18)F-FDG PET/CT radiomic features. *Transl Lung*  
567 *Cancer Res.* 2020; 9(3): 549-562.
- 568 23 Yang L, Xu P, Li M et al. PET/CT radiomic features: a potential biomarker for  
569 EGFR mutation status and survival outcome prediction in NSCLC patients  
570 treated with TKIs. *Front Oncol.* 2022; 12: 894323.
- 571 24 Hong D, Xu K, Zhang L et al. Radiomics signature as a predictive factor for  
572 EGFR mutations in advanced lung adenocarcinoma. *Front Oncol.* 2020; 10: 28.
- 573 25 Lu J, Ji X, Wang L et al. Machine learning-based radiomics for prediction of  
574 epidermal growth factor receptor mutations in lung adenocarcinoma. *Dis*  
575 *Markers.* 2022; 2022: 2056837.
- 576 26 Wu S, Shen G, Mao J et al. CT radiomics in predicting EGFR mutation in non-  
577 small cell lung cancer: a single institutional study. *Front Oncol.* 2020; 10:  
578 542957.
- 579 27 Yang C, Chen W, Gong G et al. Application of CT radiomics features to predict  
580 the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung  
581 adenocarcinoma. *Transl Cancer Res.* 2020; 9(11): 6683-6690.
- 582 28 Zhang L, Chen B, Liu X et al. Quantitative biomarkers for prediction of  
583 epidermal growth factor receptor mutation in non-small cell lung cancer. *Transl*  
584 *Oncol.* 2018; 11(1): 94-101.
- 585 29 Zhu Y, Guo YB, Xu D et al. A computed tomography (CT)-derived radiomics  
586 approach for predicting primary co-mutations involving TP53 and epidermal  
587 growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas  
588 (LUAD). *Ann Transl Med.* 2021; 9(7): 545.
- 589 30 Aide N, Weyts K, Lasnon C. Prediction of the presence of targetable molecular  
590 alteration(s) with clinico-metabolic (18) F-FDG PET radiomics in non-Asian  
591 lung adenocarcinoma patients. *Diagnostics (Basel).* 2022; 12(10).
- 592 31 Li Y, Lu L, Xiao M et al. CT slice thickness and convolution Kernel affect  
593 performance of a radiomic model for predicting egfr status in non-small cell  
594 lung cancer: a preliminary study. *Sci Rep.* 2018; 8(1): 17913.

- 595 32 Zhu H, Song Y, Huang Z et al. Accurate prediction of epidermal growth factor  
596 receptor mutation status in early-stage lung adenocarcinoma, using radiomics  
597 and clinical features. *Asia Pac J Clin Oncol*. 2022; 18(6): 586-594.
- 598 33 Dong Y, Jiang Z, Li C et al. Development and validation of novel radiomics-  
599 based nomograms for the prediction of EGFR mutations and Ki-67 proliferation  
600 index in non-small cell lung cancer. *Quant Imaging Med Surg*. 2022; 12(5):  
601 2658-2671.
- 602 34 Aerts HJ, Grossmann P, Tan Y et al. Defining a radiomic response phenotype: a  
603 pilot study using targeted therapy in NSCLC. *Sci Rep*. 2016; 6: 33860.
- 604 35 Huang Q, Lu L, Dercle L et al. Interobserver variability in tumor contouring  
605 affects the use of radiomics to predict mutational status. *J Med Imaging*  
606 *(Bellingham)*. 2018; 5(1): 011005.
- 607 36 Feng Y, Song F, Zhang P et al. Prediction of EGFR mutation status in non-small  
608 cell lung cancer based on ensemble learning. *Front Pharmacol*. 2022; 13:  
609 897597.
- 610 37 Huang X, Sun Y, Tan M et al. Three-dimensional convolutional neural network-  
611 based prediction of epidermal growth factor receptor expression status in  
612 patients with non-small cell lung cancer. *Front Oncol*. 2022; 12: 772770.
- 613 38 Jia TY, Xiong JF, Li XY et al. Identifying EGFR mutations in lung  
614 adenocarcinoma by noninvasive imaging using radiomics features and random  
615 forest modeling. *Eur Radiol*. 2019; 29(9): 4742-4750.
- 616 39 Liu G, Xu Z, Ge Y et al. 3D radiomics predicts EGFR mutation, exon-19  
617 deletion and exon-21 L858R mutation in lung adenocarcinoma. *Transl Lung*  
618 *Cancer Res*. 2020; 9(4): 1212-1224.
- 619 40 Mei D, Luo Y, Wang Y et al. CT texture analysis of lung adenocarcinoma: can  
620 Radiomic features be surrogate biomarkers for EGFR mutation statuses. *Cancer*  
621 *Imaging*. 2018; 18(1): 52.
- 622 41 Zhang T, Xu Z, Liu G et al. Simultaneous identification of  
623 EGFR, KRAS, ERBB2, and TP53 mutations in patients with non-small cell lung  
624 cancer by machine learning-derived three-dimensional radiomics. *Cancers*  
625 *(Basel)*. 2021; 13(8).
- 626 42 Song J, Ding C, Huang Q et al. Deep learning predicts epidermal growth factor  
627 receptor mutation subtypes in lung adenocarcinoma. *Med Phys*. 2021; 48(12):  
628 7891-7899.
- 629 43 Wang C, Xu X, Shao J et al. Deep learning to predict EGFR mutation and PD-  
630 L1 expression status in non-small-cell lung cancer on computed tomography  
631 images. *J Oncol*. 2021; 2021: 5499385.
- 632 44 Huang W, Wang J, Wang H et al. PET/CT based egfr mutation status  
633 classification of NSCLC using deep learning features and radiomics features.  
634 *Front Pharmacol*. 2022; 13: 898529.
- 635 45 Kawazoe Y, Shiinoki T, Fujimoto K et al. Investigation of the combination of  
636 intratumoral and peritumoral radiomic signatures for predicting epidermal

- 637 growth factor receptor mutation in lung adenocarcinoma. *J Appl Clin Med Phys.*  
638 2023; 24(6): e13980.
- 639 46 Lu X, Li M, Zhang H et al. A novel radiomic nomogram for predicting  
640 epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.  
641 *Phys Med Biol.* 2020; 65(5): 055012.
- 642 47 Wang J, Lv X, Huang W et al. Establishment and optimization of radiomics  
643 algorithms for prediction of KRAS gene mutation by integration of NSCLC  
644 gene mutation mutual exclusion information. *Front Pharmacol.* 2022; 13:  
645 862581.
- 646 48 Yang X, Fang C, Li C et al. Can CT radiomics detect acquired T790M mutation  
647 and predict prognosis in advanced lung adenocarcinoma with progression after  
648 first- or second-generation EGFR TKIs? *Front Oncol.* 2022; 12: 904983.
- 649 49 Chang C, Zhou S, Yu H et al. A clinically practical radiomics-clinical combined  
650 model based on PET/CT data and nomogram predicts EGFR mutation in lung  
651 adenocarcinoma. *Eur Radiol.* 2021; 31(8): 6259-6268.
- 652 50 Dong Y, Hou L, Yang W et al. Multi-channel multi-task deep learning for  
653 predicting EGFR and KRAS mutations of non-small cell lung cancer on CT  
654 images. *Quant Imaging Med Surg.* 2021; 11(6): 2354-2375.
- 655 51 Gao J, Niu R, Shi Y et al. The predictive value of [(18)F]FDG PET/CT  
656 radiomics combined with clinical features for EGFR mutation status in different  
657 clinical staging of lung adenocarcinoma. *EJNMMI Res.* 2023; 13(1): 26.
- 658 52 Huo JW, Luo TY, Diao L et al. Using combined CT-clinical radiomics models to  
659 identify epidermal growth factor receptor mutation subtypes in lung  
660 adenocarcinoma. *Front Oncol.* 2022; 12: 846589.
- 661 53 Jiang M, Yang P, Li J et al. Computed tomography-based radiomics  
662 quantification predicts epidermal growth factor receptor mutation status and  
663 efficacy of first-line targeted therapy in lung adenocarcinoma. *Front Oncol.*  
664 2022; 12: 985284.
- 665 54 Le NQK, Kha QH, Nguyen VH et al. Machine learning-based radiomics  
666 signatures for EGFR and KRAS mutations prediction in non-small-cell lung  
667 cancer. *Int J Mol Sci.* 2021; 22(17).
- 668 55 Li S, Li Y, Zhao M et al. Combination of (18)F-fluorodeoxyglucose PET/CT  
669 radiomics and clinical features for predicting epidermal growth factor receptor  
670 mutations in lung adenocarcinoma. *Korean J Radiol.* 2022; 23(9): 921-930.
- 671 56 Li S, Luo T, Ding C et al. Detailed identification of epidermal growth factor  
672 receptor mutations in lung adenocarcinoma: Combining radiomics with machine  
673 learning. *Med Phys.* 2020; 47(8): 3458-3466.
- 674 57 Li X, Yin G, Zhang Y et al. Predictive power of a radiomic signature based on  
675 (18)F-FDG PET/CT images for EGFR mutational status in NSCLC. *Front*  
676 *Oncol.* 2019; 9: 1062.
- 677 58 Li XY, Xiong JF, Jia TY et al. Detection of epithelial growth factor receptor  
678 (EGFR) mutations on CT images of patients with lung adenocarcinoma using

- 679 radiomics and/or multi-level residual convolutionary neural networks. *J Thorac*  
680 *Dis.* 2018; 10(12): 6624-6635.
- 681 59 Liu Y, Zhou J, Wu J et al. Development and validation of machine learning  
682 models to predict epidermal growth factor receptor mutation in non-small cell  
683 lung cancer: a multi-center retrospective radiomics study. *Cancer Control.* 2022;  
684 29: 10732748221092926.
- 685 60 Ninomiya K, Arimura H, Chan WY et al. Robust radiogenomics approach to the  
686 identification of EGFR mutations among patients with NSCLC from three  
687 different countries using topologically invariant Betti numbers. *PLoS One.* 2021;  
688 16(1): e0244354.
- 689 61 Ninomiya K, Arimura H, Tanaka K et al. Three-dimensional topological  
690 radiogenomics of epidermal growth factor receptor Del19 and L858R mutation  
691 subtypes on computed tomography images of lung cancer patients. *Comput*  
692 *Methods Programs Biomed.* 2023; 236: 107544.
- 693 62 Rios Velazquez E, Parmar C, Liu Y et al. Somatic mutations drive distinct  
694 imaging phenotypes in lung cancer. *Cancer Res.* 2017; 77(14): 3922-3930.
- 695 63 Rossi G, Barabino E, Fedeli A et al. Radiomic detection of EGFR mutations in  
696 NSCLC. *Cancer Res.* 2021; 81(3): 724-731.
- 697 64 Tu W, Sun G, Fan L et al. Radiomics signature: A potential and incremental  
698 predictor for EGFR mutation status in NSCLC patients, comparison with CT  
699 morphology. *Lung Cancer.* 2019; 132: 28-35.
- 700 65 Wang C, Ma J, Shao J et al. Predicting EGFR and PD-L1 status in NSCLC  
701 patients using multitask ai system based on CT images. *Front Immunol.* 2022;  
702 13: 813072.
- 703 66 Weng Q, Hui J, Wang H et al. Radiomic feature-based nomogram: a novel  
704 technique to predict EGFR-activating mutations for EGFR tyrosin kinase  
705 inhibitor therapy. *Front Oncol.* 2021; 11: 590937.
- 706 67 Yang X, Liu M, Ren Y et al. Using contrast-enhanced CT and non-contrast-  
707 enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics  
708 nomogram analysis. *Eur Radiol.* 2022; 32(4): 2693-2703.
- 709 68 Zhang B, Qi S, Pan X et al. Deep CNN model using CT radiomics feature  
710 mapping recognizes EGFR gene mutation status of lung adenocarcinoma. *Front*  
711 *Oncol.* 2020; 10: 598721.
- 712 69 Zhang G, Cao Y, Zhang J et al. Predicting EGFR mutation status in lung  
713 adenocarcinoma: development and validation of a computed tomography-based  
714 radiomics signature. *Am J Cancer Res.* 2021; 11(2): 546-560.
- 715 70 Zhang M, Bao Y, Rui W et al. Performance of (18)F-FDG PET/CT radiomics for  
716 predicting EGFR mutation status in patients with non-small cell lung cancer.  
717 *Front Oncol.* 2020; 10: 568857.
- 718 71 Zhao HY, Su YX, Zhang LH et al. Prediction model based on 18F-FDG PET/CT  
719 radiomic features and clinical factors of EGFR mutations in lung  
720 adenocarcinoma. *Neoplasma.* 2022; 69(1): 233-241.

- 721 72 Chang C, Sun X, Wang G et al. A machine learning model based on PET/CT  
722 radiomics and clinical characteristics predicts ALK rearrangement status in lung  
723 adenocarcinoma. *Front Oncol.* 2021; 11: 603882.
- 724 73 Ma DN, Gao XY, Dan YB et al. Evaluating solid lung adenocarcinoma  
725 anaplastic lymphoma kinase gene rearrangement using noninvasive radiomics  
726 biomarkers. *Onco Targets Ther.* 2020; 13: 6927-6935.
- 727 74 Song L, Zhu Z, Mao L et al. Clinical, conventional ct and radiomic feature-based  
728 machine learning models for predicting ALK rearrangement status in lung  
729 adenocarcinoma patients. *Front Oncol.* 2020; 10: 369.
- 730 75 Hendriks LE, Kerr KM, Menis J et al. Oncogene-addicted metastatic non-small-  
731 cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and  
732 follow-up. *Ann Oncol.* 2023; 34(4): 339-357.
- 733 76 Ettinger DS, Wood DE, Aisner DL et al. Non-Small Cell Lung Cancer, Version  
734 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc*  
735 *Netw.* 2022; 20(5): 497-530.
- 736 77 Ferry-Galow KV, Datta V, Makhlof HR et al. What can be done to improve  
737 research biopsy quality in oncology clinical trials? *J Oncol Pract.* 2018; 14(11):  
738 Jop1800092.
- 739 78 Gutierrez ME, Choi K, Lanman RB et al. Genomic profiling of advanced non-  
740 small cell lung cancer in community settings: gaps and opportunities. *Clin Lung*  
741 *Cancer.* 2017; 18(6): 651-659.
- 742 79 Fornacon-Wood I, Faivre-Finn C, O'Connor JPB et al. Radiomics as a  
743 personalized medicine tool in lung cancer: separating the hope from the hype.  
744 *Lung Cancer.* 2020; 146: 197-208.
- 745 80 Neri E, Del Re M, Paiar F et al. Radiomics and liquid biopsy in oncology: the  
746 holons of systems medicine.  
747 *Insights Imaging.* 2018; 9(6): 915-924.
- 748 81 Nguyen HS, Ho DKN, Nguyen NN et al. Predicting EGFR mutation status in  
749 non-small cell lung cancer using artificial intelligence: a systematic review and  
750 meta-analysis. *Acad Radiol.* 2023.
- 751 82 Steinert HC. PET and PET-CT of lung cancer. *Methods Mol Biol.* 2011; 727: 33-  
752 51.
- 753 83 Alwosheel A, van Cranenburgh S, Chorus CG. Is your dataset big enough?  
754 Sample size requirements when using artificial neural networks for discrete  
755 choice analysis. *J Choice Model.* 2018; 28: 167-182.
- 756 84 Rajput D, Wang W-J, Chen C-C. Evaluation of a decided sample size in machine  
757 learning applications. *BMC Bioinformatics.* 2023; 24(1): 48.
- 758 85 Mu W, Jiang L, Zhang J et al. Non-invasive decision support for NSCLC  
759 treatment using PET/CT radiomics. *Nat Commun.* 2020; 11(1): 5228.
- 760 86 Zhao W, Yang J, Ni B et al. Toward automatic prediction of EGFR mutation  
761 status in pulmonary adenocarcinoma with 3D deep learning. *Cancer Med.* 2019;  
762 8(7): 3532-3543.



- 763 87 Zuo Y, Liu Q, Li N et al. Optimal (18)F-FDG PET/CT radiomics model  
764 development for predicting EGFR mutation status and prognosis in lung  
765 adenocarcinoma: a multicentric study. *Front Oncol.* 2023; 13: 1173355.
- 766 88 Shiri I, Amini M, Nazari M et al. Impact of feature harmonization on  
767 radiogenomics analysis: prediction of EGFR and KRAS mutations from non-  
768 small cell lung cancer PET/CT images. *Comput Biol Med.* 2022; 142: 105230.
- 769 89 Yip SSF, Parmar C, Kim J et al. Impact of experimental design on PET  
770 radiomics in predicting somatic mutation status. *Eur J Radiol.* 2017; 97: 8-15.
- 771 90 Shao J, Ma J, Zhang S et al. Radiogenomic system for non-invasive  
772 identification of multiple actionable mutations and PD-L1 expression in non-  
773 small cell lung cancer based on ct images. *Cancers (Basel).* 2022; 14(19).
- 774 91 Xiao Z, Cai H, Wang Y et al. Deep learning for predicting epidermal growth  
775 factor receptor mutations of non-small cell lung cancer on PET/CT images.  
776 *Quant Imaging Med Surg.* 2023; 13(3): 1286-1299.
- 777 92 Ağuloğlu N, Aksu A, Akyol M et al. Importance of pretreatment 18F-FDG  
778 PET/CT texture analysis in predicting EGFR and ALK mutation in patients with  
779 non-small cell lung cancer. *Nuklearmedizin.* 2022; 61(6): 433-439.
- 780 93 Agazzi GM, Ravanelli M, Roca E et al. CT texture analysis for prediction of  
781 EGFR mutational status and ALK rearrangement in patients with non-small cell  
782 lung cancer. *Radiol Med.* 2021; 126(6): 786-794.
- 783 94 Chen W, Hua Y, Mao D et al. A computed tomography-derived radiomics  
784 approach for predicting uncommon EGFR mutation in patients with NSCLC.  
785 *Front Oncol.* 2021; 11: 722106.
- 786 95 Chen Q, Li Y, Cheng Q et al. EGFR mutation status and subtypes predicted by  
787 CT-based 3D radiomic features in lung adenocarcinoma. *Onco Targets Ther.*  
788 2022; 15: 597-608.
- 789 96 Choe J, Lee SM, Kim W et al. CT radiomics-based prediction of anaplastic  
790 lymphoma kinase and epidermal growth factor receptor mutations in lung  
791 adenocarcinoma. *Eur J Radiol.* 2021; 139: 109710.
- 792 97 Digumarthy SR, Padole AM, Gullo RL et al. Can CT radiomic analysis in  
793 NSCLC predict histology and EGFR mutation status? *Medicine (Baltimore).*  
794 2019; 98(1): e13963.
- 795 98 Hao P, Deng BY, Huang CT et al. Predicting anaplastic lymphoma kinase  
796 rearrangement status in patients with non-small cell lung cancer using a machine  
797 learning algorithm that combines clinical features and CT images. *Front Oncol.*  
798 2022; 12: 994285.
- 799 99 He R, Yang X, Li T et al. A machine learning-based predictive model of  
800 epidermal growth factor mutations in lung adenocarcinomas. *Cancers (Basel).*  
801 2022; 14(19).
- 802 100 Hou D, Li W, Wang S et al. Different clinicopathologic and computed  
803 tomography imaging characteristics of primary and acquired EGFR T790M  
804 mutations in patients with non-small-cell lung cancer. *Cancer Manag Res.* 2021;  
805 13: 6389-6401.

- 806 101 Jiang M, Zhang Y, Xu J et al. Assessing EGFR gene mutation status in non-small  
807 cell lung cancer with imaging features from PET/CT. *Nucl Med Commun.* 2019;  
808 40(8): 842-849.
- 809 102 Kawazoe Y, Shiinoki T, Fujimoto K et al. Comparison of the radiomics-based  
810 predictive models using machine learning and nomogram for epidermal growth  
811 factor receptor mutation status and subtypes in lung adenocarcinoma. *Phys Eng*  
812 *Sci Med.* 2023; 46(1): 395-403.
- 813 103 Koyasu S, Nishio M, Isoda H et al. Usefulness of gradient tree boosting for  
814 predicting histological subtype and EGFR mutation status of non-small cell lung  
815 cancer on (18)F FDG-PET/CT. *Ann Nucl Med.* 2020; 34(1): 49-57.
- 816 104 Li S, Ding C, Zhang H et al. Radiomics for the prediction of EGFR mutation  
817 subtypes in non-small cell lung cancer. *Med Phys.* 2019; 46(10): 4545-4552.
- 818 105 Li H, Gao C, Sun Y et al. Radiomics analysis to enhance precise identification of  
819 epidermal growth factor receptor mutation based on positron emission  
820 tomography images of lung cancer patients. *J Biomed Nanotechnol.* 2021; 17(4):  
821 691-702.
- 822 106 Liu Y, Kim J, Balagurunathan Y et al. Radiomic features are associated with  
823 EGFR mutation status in lung adenocarcinomas. *Clin Lung Cancer.* 2016; 17(5):  
824 441-448.e446.
- 825 107 Liu Z, Zhang T, Lin L et al. Applications of radiomics-based analysis pipeline  
826 for predicting epidermal growth factor receptor mutation status. *Biomed Eng*  
827 *Online.* 2023; 22(1): 17.
- 828 108 Lu L, Sun SH, Yang H et al. Radiomics prediction of EGFR status in lung  
829 cancer-our experience in using multiple feature extractors and The Cancer  
830 Imaging Archive Data. *Tomography.* 2020; 6(2): 223-230.
- 831 109 Ruan D, Fang J, Teng X. Efficient 18F-Fluorodeoxyglucose positron emission  
832 tomography/computed tomography-based machine learning model for predicting  
833 epidermal growth factor receptor mutations in non-small cell lung cancer. *Q J*  
834 *Nucl Med Mol Imaging.* 2022.
- 835 110 Trivizakis E, Souglakos J, Karantanas A et al. Deep radiotranscriptomics of non-  
836 small cell lung carcinoma for assessing molecular and histology subtypes with a  
837 data-driven analysis. *Diagnostics (Basel).* 2021; 11(12).
- 838 111 Yamazaki M, Yagi T, Tominaga M et al. Role of intratumoral and peritumoral  
839 CT radiomics for the prediction of EGFR gene mutation in primary lung cancer.  
840 *Br J Radiol.* 2022; 95(1140): 20220374.
- 841 112 Yang B, Ji HS, Zhou CS et al. (18)F-fluorodeoxyglucose positron emission  
842 tomography/computed tomography-based radiomic features for prediction of  
843 epidermal growth factor receptor mutation status and prognosis in patients with  
844 lung adenocarcinoma. *Transl Lung Cancer Res.* 2020; 9(3): 563-574.
- 845 113 Zhang J, Zhao X, Zhao Y et al. Value of pre-therapy (18)F-FDG PET/CT  
846 radiomics in predicting EGFR mutation status in patients with non-small cell  
847 lung cancer. *Eur J Nucl Med Mol Imaging.* 2020; 47(5): 1137-1146.

- 848 114 Zhang T, Liu Z, Lin L et al. Detection of the gene mutation of epidermal growth  
849 factor receptor in lung adenocarcinoma by radiomic features from a small  
850 amount of PET data. *Nucl Med Commun.* 2023.
- 851 115 Zhao W, Wu Y, Xu Y et al. The potential of radiomics nomogram in non-  
852 invasively prediction of epidermal growth factor receptor mutation status and  
853 subtypes in lung adenocarcinoma. *Front Oncol.* 2019; 9: 1485.
- 854

**Table 1.** Methodological characteristics of the studies ( $N = 89$ ) included in the systematic review. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally indicate those that were included in the different meta-analyses and consequently, that are represented in the forest plots.

Author-Year	Imaging modality	Contrast-CT*	Tumor segmentation	Model	Classifier (ML)	Datasets			Partition strategy
						Training	Validation	Test	
Agüloğlu et al. 2022 <sup>92</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	RF NB KNN DT SVM LR	133	56	–	Training-Validation split
Aerts et al. 2016 <sup>34</sup>	CT	Non-contrast CT	Semi-automatic	Classical statistical model	–	–	–	–	–
Agazzi et al. 2021 <sup>93</sup>	CT	Contrast-enhanced	Manual	ML	GBM	104	67	–	Training-Validation split

Aide et al. 2022 <sup>30</sup>	PET	–	Manual	ML	LASSO	87	22	–	Training-Validation split
Chang et al. 2021 <sup>#49</sup>	PET/CT	Non-contrast CT	Manual	ML	LASSO	409	174	–	Training-Validation split
Chang et al. 2021 <sup>##72</sup>	PET/CT	Non-contrast CT	Manual	ML	LR <sup>†</sup>	367	159	–	Training-Validation split
Chen et al. 2021 <sup>94</sup>	CT	Non-contrast CT	Manual	ML	SVM	179	44	–	Training-Validation split
Chen et al. 2022 <sup>95</sup>	CT	Non-contrast CT	Semi-automatic	ML	LASSO	176	57	–	Training-Validation split
Choe et al. 2021 <sup>96</sup>	CT	Contrast-enhanced	Semi-automatic	ML	LR	349	154	–	Training-Validation split
Dang et al. 2021 <sup>19</sup>	CT	Non-contrast CT	Semi-automatic	ML	LASSO	88	30	–	Training-Validation split
Digumarthy et	CT	Contrast-enhanced	Not specified	Classical	–	–	–	–	–

al. 2019 <sup>97</sup>				statistical model					
Dong et al. 2022 <sup>33</sup>	CT	Non-contrast CT	Not specified	ML	LR	87	45	–	Training-Validation split
Dong et al. 2021 <sup>50</sup>	CT	Non-contrast CT	Manual	DL ML	RF	363	162	–	Training-Validation split
Feng et al. 2022 <sup>36</sup>	CT	Non-contrast CT	Manual	ML	RF XGBoost LR SVM	151	–	–	Training-Validation split
Gao et al. 2023 <sup>51</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR RF SVM	404	111	–	Training-Validation split
Hao et al. 2022 <sup>98</sup>	CT	Non-contrast CT	Manual	ML	SVM XGBoost AdaBoost LBP DT	154	39	–	Training-Validation split

					LR				
He et al. 2022 <sup>99</sup>	CT	Non-contrast CT	Semi-automatic	ML	RF KNN LGBM SVM	-	-	-	Training-Validation split
Hong et al. 2020 <sup>24</sup>	CT	Contrast-enhanced	Manual	ML	NBC KNN RF SVM DT LR	140	61	-	Training-Validation split
Huang et al. 2018 <sup>35</sup>	CT	Non-contrast CT	Semi-automatic	Classical statistical model	-	-	-	-	-
Huang et al. 2022 <sup>44</sup>	PET/CT	Non-contrast CT	Manual	DL ML	LR	138	57	-	Training-Validation split
Huang et al. 2022 <sup>37</sup>	CT	Non-contrast CT	Manual	DL	LR	770	304	-	Training-Validation split

				ML					
Huo et al. 2022 <sup>52</sup>	CT	Contrast-enhanced	Manual	ML	GBT	487	121	–	Training-Validation split
Hou et al. 2021 <sup>100</sup>	CT	Contrast-enhanced	Semi-automatic	Classical statistical model	–	144	62	–	Training-Validation split
Jia et al. 2019 <sup>38</sup>	CT	Non-contrast CT	Semi-automatic	ML	RF	345	158	–	Training-Validation split
Jiang et al. 2019 <sup>101</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	SVM	–	–	–	10-fold cross-validation
Jiang et al. 2022 <sup>53</sup>	CT	Non-contrast CT	Manual	ML	SVM	514	178	–	Training-Validation split
Kawazoe et al. 2023 <sup>45</sup>	CT	Non-contrast CT	Semi-automatic	ML	SVM LR LGBM	120	44	–	Training-Validation split
Kawazoe et al.	CT	Non-contrast CT	Semi-automatic	ML	SVM	120	52	–	Training-Validation



2023 <sup>102</sup>					LR				split
Koyasu et al. 2020 <sup>103</sup>	PET/CT	Non-contrast CT	Manual	ML	RF XGBoost	-	-	-	10-fold cross-validation
Le et al. 2021 <sup>54</sup>	CT	Non-contrast CT	Manual	ML	XGBoost	143	18	-	Training-Validation split
Li et al. 2018# <sup>58</sup>	CT	Non-contrast CT	Manual	DL ML	RF	810	200	-	Training-Validation split
Li et al. 2018 <sup>31</sup>	CT	Contrast-enhanced	Semi-automatic	ML	SVM	-	-	-	3-fold cross-validation
Li et al 2019# <sup>57</sup>	PET/CT	Non-contrast CT	Manual	ML	Boosting ML scheme	115	-	-	10-fold cross-validation
Li et al. 2019 <sup>104</sup>	CT	Non-contrast CT	Manual	ML	LR	236	76	-	Training-Validation split
Li et al. 2020 <sup>56</sup>	CT	Non-contrast CT	Manual	ML	LR SVM	326	112	-	Training-Validation split

					RF NB Neural network				
Li et al. 2021 <sup>105</sup>	PET	–	Semi-automatic	ML	SVM	50	25	–	Training-Validation split
Li et al. 2022 <sup>55</sup>	PET/CT	Non-contrast CT	Manual	ML	LR	125	54	–	Training-Validation split
Liu et al. 2016 <sup>106</sup>	CT	Non-contrast CT	Semi-automatic	Classical statistical model	–	–	–	–	–
Liu et al. 2020 <sup>#39</sup>	CT	Contrast-enhanced	Semi-automatic	ML	LR	210	53	–	Training-Validation split
Liu et al. 2020 <sup>22</sup>	PET/CT	Non-contrast CT	Manual	ML	XGBoost	111	37	–	Training-Validation split
Liu et al. 2022 <sup>59</sup>	CT	Non-contrast CT	Manual	ML	LR DT RF	296	50	–	Training-Validation split

					SVM				
Liu et al. 2023 <sup>107</sup>	PET/CT	Non-contrast CT	Manual	ML	LR DT RF SVM	-	-	-	10-fold cross-validation
Lu et al. 2020 <sup>#46</sup>	CT	Non-contrast CT	Manual	ML	LR	83	-	21	Training-Validation split
Lu et al. 2020 <sup>108</sup>	CT	Non-contrast CT	Semi-automatic	ML	KNN Bagging SVM RF	105	228	-	Training-Validation split
Lu et al. 2022 <sup>25</sup>	CT	Non-contrast CT	Manual	ML	DT AdaBoost NB RF LR SVM XGBoost	140	61	-	Training-Validation split

					KNN				
Ma et al. 2020 <sup>73</sup>	CT	Contrast-enhanced	Manual	ML	SVM	98	42	–	Training-Validation split
Mei et al. 2018 <sup>40</sup>	CT	Non-contrast CT	Manual	Classical statistical model	–	–	–	–	–
Mu et al. 2020 <sup>85</sup>	PET/CT	Non-contrast CT	Manual	DL	–	429	187	65	Training-Validation split
Nair et al. 2021 <sup>17</sup>	PET/CT	Contrast-enhanced	Manual	ML	LR	–	–	–	LOOCV
Ninomiya et al. 2021 <sup>60</sup>	CT	Contrast-enhanced	Manual	ML	SVM	99 <sup>‡</sup>	99 <sup>‡</sup>	95	Training-Validation split
Ninomiya et al. 2023 <sup>61</sup>	CT	Contrast-enhanced	Not specified	ML	SVM	92	62	–	Training-Validation split
Omura et al. 2023 <sup>20</sup>	CT	Contrast-enhanced	Automatic	ML	RF	–	–	–	Training-Validation split

Ríos Velázquez et al. 2017 <sup>62</sup>	CT	Contrast + Non-contrast CT	Semi-automatic	ML	RF	353	352	–	Training-Validation split
Rossi et al. 2021 <sup>63</sup>	CT	Non-contrast CT	Manual	ML	SVM	–	109	61	Training-Validation split
Ruan et al. 2022 <sup>109</sup>	PET/CT	Non-contrast CT	Manual	ML	SVM	70	30	–	Training-Validation split
Shao et al. 2022 <sup>90</sup>	CT	Non-contrast CT	Semi-automatic	DL	–	–	–	–	Training-Validation split
Shiri et al. 2020 <sup>18</sup>	CT low dose CTD PET/CT	Contrast-enhanced	Manual Automatic <sup>§</sup>	ML	SVM KNN DT QDA MLP SGD LR NB GNB	82	68	–	10-fold cross-validation

					RF AdaBoost Bagging				
Shiri et al. 2022 <sup>88</sup>	PET/CT	Non-contrast CT	Manual Automatic <sup>§</sup>	ML	RF	-	-	-	Training-Validation split
Song et al. 2021 <sup>42</sup>	CT	Not specified	Manual Automatic	DL ML	SVM	528	137	-	Training-Validation split
Song et al. 2020 <sup>74</sup>	CT	Non-contrast CT	Automatic	ML	DT	268	67	-	Training-Validation split
Trivizakis et al. 2021 <sup>110</sup>	CT	Not specified	Not specified	DL ML	KNN DT RBF-GPC RBF-SVM Linear SVM Polynomial SVM Sigmoid SVM	-	-	-	5-fold cross-validation

Tu et al. 2019 <sup>64</sup>	CT	Non-contrast CT	Not specified	ML	LR	243	161	–	Training-Validation split
Wang et al. 2019 <sup>21</sup>	CT	Contrast-enhanced	Manual	ML	SVM	41	–	–	Training-Validation split
Wang et al. 2021 <sup>43</sup>	CT	Non-contrast CT	Manual	DL	–	882	125	255	Training-Validation split
Wang et al. 2022 <sup>#65</sup>	CT	Non-contrast CT	Manual	DL ML	LASSO	–	–	–	Training-Validation split <sup>¶</sup>
Wang et al. 2022 <sup>##47</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR	180	78	–	Training-Validation split
Weng et al. 2021 <sup>66</sup>	CT	Non-contrast CT	Semi-automatic	ML	LR	210	91	–	Training-Validation split
Wu et al. 2020 <sup>26</sup>	CT	Contrast-enhanced	Manual	ML	LR	–	–	–	10-fold cross-validation
Xiao et al.	PET/CT	Non-contrast CT	Manual	DL	RF	121	29	–	Training-Validation

2023 <sup>91</sup>				ML					split
Yamazaki et al. 2022 <sup>111</sup>	CT	Non-contrast CT	Semi-automatic	ML	RF	-	-	-	-
Yang et al. 2020 <sup>#27</sup>	CT	Contrast-enhanced	Semi-automatic	ML	LASSO	130	40	-	Training-Validation split
Yang et al. 2020 <sup>112</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	RF	139	35	-	Training-Validation split
Yang et al. 2022 <sup>#67</sup>	CT	Contrast + Non-contrast CT	Manual	ML	LR RF SVM GBT NB	327	66	19	Training-Validation split
Yang et al. 2022 <sup>23</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	SVM DT RF	218	95	-	Training-Validation split
Yang et al.	CT	Contrast-enhanced	Manual	ML	LR	176	74	-	Training-Validation



2022 <sup>48</sup>									split
Yip et al. 2017 <sup>89</sup>	PET	–	Manual	Classical statistical model	–	–	–	–	–
Zhang et al. 2018 <sup>28</sup>	CT	Non-contrast CT	Manual	ML	LR	140	40	–	Training-Validation split
Zhang et al. 2020 <sup>#70</sup>	PET/CT	Non-contrast CT	Manual	ML	RF SVM LR	–	–	–	10-fold cross-validation
Zhang et al. 2020 <sup>113</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR	175	73	–	Training-Validation split
Zhang et al. 2020 <sup>##68</sup>	CT	Non-contrast CT	Semi-automatic	DL ML	RF SVM	638	71	205	Training-Validation split
Zhang et al.	CT	Contrast-enhanced	Semi-automatic	ML	LASSO	–	–	–	Training-Validation

2021 <sup>41</sup>									split
Zhang et al. 2021 <sup>69</sup>	CT	Non-contrast CT	Manual	ML	DT LR SVM Multivariate analysis for C-R-R model	294	126	-	Training-Validation split
Zhang et al. 2023 <sup>114</sup>	PET	-	Manual	ML	SVM RF LR AdaBoost	-	-	-	10-fold cross-validation
Zhao et al. 2019 <sup>86</sup>	CT	Non-contrast CT	Manual	DL ML	LR	348	116	116	Training-Validation split
Zhao et al. 2019 <sup>115</sup>	CT	Non-contrast CT	Manual	ML	LR	322	315	-	Training-Validation split
Zhao et al. 2022 <sup>71</sup>	PET/CT	Non-contrast CT	Semi-automatic	ML	LR	65	23	-	Training-Validation split

Zhu et al. 2022 <sup>32</sup>	CT	Non-contrast CT	Semi-automatic	ML	LASSO RF SVM	875	217	–	Training-Validation split
Zhu et al. 2021 <sup>29</sup>	CT	Contrast-enhanced	Manual	ML	SVM KNN RF LR	159	40	–	Training-Validation split
Zuo et al. 2023 <sup>87</sup>	PET/CT	Non-contrast CT	Manual	ML	LGBM XGBoost RF LR	410	170	180	Training-Validation split

\*In studies in which PET/CT was performed, only details about contrast were provided for PET acquisition. Consequently, it was assumed that CT scans were non-contrast enhanced.

†Not specified but inferred from the methodology and results.

‡Number of cases for training and validation sets not specified; only a total number for both cohorts provided.

§Manual segmentation for PET images; automatic segmentation for CT images.

¶80% Training-Validation split.

CT, computed tomography; CTD, contrast-enhanced diagnostic quality; DL, deep learning; DT, decision tree; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2;

---

GBM, gradient boosted machine; GBT, gradient boosting tree; GNB, Gaussian Naives Bayes; GPC, Gaussian processes classification; LASSO, least absolute shrinkage and selection operator; LBP, local binary pattern; LGBM, Light gradient boosted machine; LOOCV, leave-one-out cross-validation; LR, logistic regression; ML, machine learning; MLP, multilayer perceptron; NB, Naive Bayes; KNN, K-nearest neighbors; PET, positron emission tomography; QDA, quadratic discriminant analysis; RBF, radial basis function; RF, random forest; SGD, stochastic gradient descent; SVM, support vector machine; TP53, tumor suppressor protein 53.

**Table 2.** Clinical characteristics of the studies ( $N = 89$ ) included in the systematic review. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally indicate those that were included in the different meta-analyses and consequently, that are represented in the forest plots.

Author-Year	Target oncogene mutation	Design	Total of patients	Sex		Age Mean/median	Histology	Smoking status		TNM stage	Treatment
				Female	Male			Current /former smoker	Non-smoker		
Agüloğlu et al. 2022 <sup>92</sup>	EGFR ALK	Unicentric	189	59	130	62/-	NSCLC	130	59	Stages I-IV	Naïve
Aerts et al. 2016 <sup>34</sup>	EGFR	Unicentric	47	-	-	-/-	NSCLC	-	-	-	Naïve + post-treatment images
Agazzi et al. 2021 <sup>93</sup>	EGFR ALK	Unicentric	84	39	45	-/63	ADC	57	27	-	Naïve
Aide et al. 2022 <sup>30</sup>	EGFR	Unicentric	109	34	75	-/66	ADC	96	13	Stages II-IV	Naïve

Chang et al. 2021 <sup>#49</sup>	EGFR	Unicentric	583	305	278	-/62	ADC	229	354	Stages I-III	Naïve
Chang et al. 2021 <sup>##72</sup>	ALK	Unicentric	526	272	254	-/58.25	ADC	202	324	Stages I-IV	Naïve
Chen et al. 2021 <sup>94</sup>	EGFR	Unicentric	223	109	114	64.63/-	NSCLC	55	168	Stages I-IV	Naïve
Chen et al. 2022 <sup>95</sup>	EGFR	Unicentric	233	105	128	57.5/-	ADC	65	168	Stages I-IV	Naïve
Choe et al. 2021 <sup>96</sup>	ALK	Unicentric	503	273	230	62.5/-	ADC	200	303	Stages I-IV	Not specified
Dang et al. 2021 <sup>19</sup>	EGFR	Not specified	118	55	63	63.82/-	ADC, SCC	-	-	Stages I-III	No treatment*
Digumarthy et al. 2019 <sup>97</sup>	EGFR	Unicentric	93	50	43	60/-	ADC, SCC	61	32	-	Naïve
Dong et al. 2022 <sup>33</sup>	EGFR	Multicentric	132	64	68	58.8/-	NSCLC	42	90	Stages I-III	Naïve
Dong et al.	EGFR	Multicentric	525	250	275	-/65.5	NSCLC	373	152	-	Not specified

2021 <sup>50</sup>	KRAS										
Feng et al. 2022 <sup>36</sup>	EGFR	Multicentric	168	–	–	–/–	NSCLC	–	–	–	Not specified <sup>†</sup>
Gao et al. 2023 <sup>51</sup>	EGFR	Unicentric	515	264	251	64/–	ADC	175	–	Stages I-IV	Naïve
Hao et al. 2022 <sup>98</sup>	ALK	Unicentric	193	102	91	54.26/–	NSCLC	49	144	Stages II and IV	Naïve
He et al. 2022 <sup>99</sup>	EGFR	Multicentric	758	317	441	55.6/–	NSCLC	358	400	Stages I-IV	Naïve
Hong et al. 2020 <sup>24</sup>	EGFR	Unicentric	201	94	107	58.12/–	ADC	64	137	Stages I-IV	Naïve
Huang et al. 2018 <sup>35</sup>	EGFR	Unicentric	46	–	–	–/–	NSCLC	–	–	–	Naïve + post-treatment images
Huang et al. 2022 <sup>44</sup>	EGFR	Unicentric	195	72	123	61.14 –	NSCLC	127	68	–	No treatment*
Huang et al. 2022 <sup>37</sup>	EGFR	Unicentric	1074	–	–	–/–	NSCLC	–	–	–	Not specified

Huo et al. 2022 <sup>52</sup>	EGFR	Unicentric	608	272	336	61.7/-	ADC	0	335	Stages II and IV	Naïve
Hou et al. 2021 <sup>100</sup>	EGFR	Unicentric	206	120	86	-/59	ADC, SCC, ASC <sup>‡</sup>	57	-	Stages I-IV	Naïve
Jia et al. 2019 <sup>38</sup>	EGFR	Unicentric	503	249	254	-/60.5	ADC	80	423	Stages I-IV	Not specified <sup>†</sup>
Jiang et al. 2019 <sup>101</sup>	EGFR	Unicentric	80	32	48	64/62.5	NSCLC	21	59	-	Naïve
Jiang et al. 2022 <sup>53</sup>	EGFR	Unicentric	692	-	-	59/-	ADC	-	-	-	Naïve
Kawazoe et al. 2023 <sup>45</sup>	EGFR	Unicentric	164	75	89	70.24/-	ADC	102	62	Stages I-IV	No treatment <sup>§</sup>
Kawazoe et al. 2023 <sup>102</sup>	EGFR	Unicentric	172	77	95	70.76/-	ADC	107	65	Stages I-IV	Naïve
Koyasu et al. 2020 <sup>103</sup>	EGFR	Unicentric	138	54	84	67.8/-	ADC, SCC	-	-	-	Not specified



Le et al. 2021 <sup>54</sup>	EGFR KRAS	Multicentric	161	50	111	68.05/–	ADC, NSCLC NOS, SCC	61	100	–	Naïve
Li et al. 2018 <sup>#58</sup>	EGFR	Unicentric	1010	457	553	–/63	ADC	262	748	Stages I-IV	Naïve
Li et al. 2018 <sup>31</sup>	EGFR	Unicentric	51	19	32	58.1/–	ADC	24	27	Stages I-III	Not specified <sup>†</sup>
Li et al 2019 <sup>#57</sup>	EGFR	Unicentric	115	62	53	–/63	NSCLC	36	79	Stages II and IV	Naïve
Li et al. 2019 <sup>104</sup>	EGFR	Unicentric	312	164	148	Freq./Freq. <sup>‡</sup>	ADC, SCC	109	203	Stages II and IV	Naïve
Li et al. 2020 <sup>56</sup>	EGFR	Multicentric	438	–	–	61.31/–	ADC	–	–	–	Naïve
Li et al. 2021 <sup>105</sup>	EGFR	Unicentric	75	45	30	62/–	Lung cancer <sup>**</sup>	34	41	–	Not specified
Li et al. 2022 <sup>55</sup>	EGFR	Unicentric	179	103	76	61.51/59.5	ADC	65	114	–	Naïve
Liu et al. 2016 <sup>106</sup>	EGFR	Unicentric	298	172	126	–/60	ADC, Others	136	162	Stages II and IV	Naïve

Liu et al. 2020 <sup>#39</sup>	EGFR	Unicentric	263	121	142	62.5/-	ADC	31	232	-	Not specified <sup>†</sup>
Liu et al. 2020 <sup>22</sup>	EGFR	Unicentric	148	63	85	-/61.2	ADC	-	-	Stages II-IV	Naïve
Liu et al. 2022 <sup>59</sup>	EGFR	Multicentric	346	141	205	66.69/-	ADC, SCC, LCC, PSC	225	121	-	Naïve
Liu et al. 2023 <sup>107</sup>	EGFR	Unicentric	115	62	53	-/62.75	ADC	36	79	Stages I-IV	Naïve
Lu et al. 2020 <sup>#46</sup>	EGFR	Unicentric	104	64	40	58.27/-	ADC	30	74	Stages I-IV	No treatment*
Lu et al. 2020 <sup>108</sup>	EGFR	Multicentric	228 <sup>††</sup>	85 <sup>††</sup>	120 <sup>††</sup>	67.94/-	ADC, SCC, NOS	-	-	Stages 0-IV	Not specified
Lu et al. 2022 <sup>25</sup>	EGFR	Unicentric	201	99	102	64.81/-	ADC	84	117	Stages III-IV	Naïve
Ma et al. 2020 <sup>73</sup>	ALK	Unicentric	140	87	53	54.19/-	ADC	45	95	Stages II and IV	Naïve
Mei et al. 2018 <sup>40</sup>	EGFR	Unicentric	296	144	152	58.56/-	ADC	86	210	-	Not specified <sup>†</sup>

Mu et al. 2020 <sup>85</sup>	EGFR	Multicentric	681	303	378	61,83/–	ADC, SCC	315	366	Stages I-IV	Naïve
Nair et al. 2021 <sup>17</sup>	EGFR	Unicentric	50	18	32	–/–	NSCLC	35	15	–	Naïve
Ninomiya et al. 2021 <sup>60</sup>	EGFR	Multicentric	194	74	120	–/67	NSCLC	128	66	Stages I-IV	Not specified
Ninomiya et al. 2023 <sup>61</sup>	EGFR	Multicentric	154	86	68	–/67	Lung cancer	73	81	Stages I-IV	Not specified
Omura et al. 2023 <sup>20</sup>	EGFR	Unicentric	99	65	34	66/–	ADC	41	–	Stages I-II	Naïve
Ríos Velázquez et al. 2017 <sup>62</sup>	EGFR KRAS	Multicentric	763	459	304	65/–	ADC	548	215	Stages I-IV	Not specified
Rossi et al.	EGFR	Multicentric	170	–	–	–/–	ADC	110	30	–	Naïve

2021 <sup>63</sup>											
Ruan et al. 2022 <sup>109</sup>	EGFR	Unicentric	100	42	58	– / 64.5	NSCLC	33	67	Stages I-IV	Naïve
Shao et al. 2022 <sup>90</sup>	EGFR	Unicentric	1096	–	–	58.26/–	NSCLC	–	–	–	Naïve
Shiri et al. 2020 <sup>18</sup>	EGFR KRAS	Unicentric	150	–	–	69.1 –	ADC, SCC, NOS <sup>‡</sup>	–	–	–	Not specified
Shiri et al. 2022 <sup>88</sup>	EGFR KRAS	Multicentric	136	–	–	–/–	ADC, SCC, NOS	–	–	–	Not specified
Song et al. 2021 <sup>42</sup>	EGFR	Multicentric	665	336	329	Freq./Freq. <sup>¶</sup>	ADC	334	331	Stages II and IV	Not specified <sup>**</sup>
Song et al. 2020 <sup>74</sup>	ALK	Unicentric	335	196	139	57 / –	ADC	103	232	Stages I-IV	Naïve

Trivizakis et al. 2021 <sup>110</sup>	EGFR	Unicentric	112	–	–	–/–	ADC, SCC	–	–	–	Not specified
Tu et al. 2019 <sup>64</sup>	EGFR	Unicentric	404	211	193	59.95/–	NSCLC	114	290	Stages II and IV	Naïve
Wang et al. 2019 <sup>21</sup>	EGFR	Unicentric	51	35	16	58.45/–	ADC	9	42	Stages 0-II	Not specified
Wang et al. 2021 <sup>43</sup>	EGFR PD-L1	Unicentric	1262	642	620	57.7/–	ADC, SCC, Others <sup>‡</sup>	452	749	Stages I-IV	Not specified <sup>§§</sup>
Wang et al. 2022 <sup>#65</sup>	EGFR PD-L1	Unicentric	3629	1674	1955	59.29/–	ADC, SCC, Others	1413	1981	Stages I-IV	Naïve
Wang et al. 2022 <sup>##47</sup>	KRAS	Unicentric	258	78	180	62.35/–	NSCLC	166	92	–	No treatment*
Weng et al. 2021 <sup>66</sup>	EGFR	Unicentric	301	145	156	64.95/–	NSCLC	110	191	–	Naïve

Wu et al. 2020 <sup>26</sup>	EGFR	Unicentric	67	29	38	56.35/-	ADC, SCC	34	33	Stages III-IV	Naïve
Xiao et al. 2023 <sup>91</sup>	EGFR	Unicentric	150	59	91	-/58	NSCLC	64	86	-	Not specified
Yamazaki et al. 2022 <sup>111</sup>	EGFR	Unicentric	478	190	288	Freq./Freq. <sup>¶</sup>	ADC, SCC, Others <sup>‡</sup>	-	-	Stages II and IV	Naïve
Yang et al. 2020 <sup>#27</sup>	EGFR	Unicentric	253	155	98	-/62	ADC	105	148	Stages III-IV	Naïve
Yang et al. 2020 <sup>112</sup>	EGFR	Unicentric	174	81	93	61.72/-	ADC	59	115	Stages II and IV	Naïve
Yang et al. 2022 <sup>#67</sup>	EGFR	Unicentric	412	223	189	62/-	ADC, SCC	105	307	-	Naïve
Yang et al. 2022 <sup>23</sup>	EGFR	Unicentric	313	164	149	59.21/-	ADC	105	208	Stages II-IV	Naïve
Yang et al. 2022 <sup>48</sup>	EGFR	Unicentric	250	-	-	56.35 / -	ADC	-	-	-	Treated with TKIs <sup>¶¶</sup>

Yip et al. 2017 <sup>89</sup>	KRAS	Unicentric	348	214	134	–/65	ADC, NSCLC NOS, SC. Not available for 1 patient <sup>‡</sup>	286	62	Stages I-IV	Naïve
Zhang et al. 2018 <sup>28</sup>	EGFR	Unicentric	180	46	134	59.7/–	ADC, SCC, Others	119	61	Stages III-IV	Naïve
Zhang et al. 2020# <sup>70</sup>	EGFR	Unicentric	173	58	115	60.8/–	ADC SCC, LCC, NSCLC- NOS	–	–	Stages I-IV	Naïve
Zhang et al. 2020 <sup>113</sup>	EGFR	Unicentric	248	113	135	62.23/–	ADC	117	131	Stages I-IV	Naïve
Zhang et al. 2020## <sup>68</sup>	EGFR	Unicentric	914	493	421	59.79/–	ADC	–	–	–	Naïve

Zhang et al. 2021 <sup>41</sup>	EGFR KRAS ERBB2 TP53	Unicentric	134	56	78	63.6/-	ADC, SCC, ASC	28	106	-	Not specified
Zhang et al. 2021 <sup>69</sup>	EGFR	Unicentric	420	201	219	57.43/56.5	ADC	147	273	-	Naïve
Zhang et al. 2023 <sup>114</sup>	EGFR	Unicentric	115	-	-	-/-	NSCLC	-	-	-	Naïve
Zhao et al. 2019 <sup>86</sup>	EGFR	Unicentric	579	334	245	60.1/-	ADC	-	-	Stages 0-IV	Not specified
Zhao et al. 2019 <sup>115</sup>	EGFR	Unicentric	637	368	269	59.9/-	ADC	49	588	-	Naïve
Zhao et al. 2022 <sup>71</sup>	EGFR	Unicentric	88	39	49	64.23/-	ADC	31	57	Stages II and IV	Naïve
Zhu et al. 2022 <sup>32</sup>	EGFR	Unicentric	1092	648	442	59.59/-	ADC	-	-	Stages I-III	Naïve



Zhu et al. 2021 <sup>29</sup>	EGFR TP53	Unicentric	199	86	113	Freq./Freq. <sup>¶</sup>	ADC	94	105	Stages III-IV	Naïve
Zuo et al. 2023 <sup>87</sup>	EGFR	Multicentric	767	372	395	-/62.04	ADC	-	-	Stages I-IV Others (34 patients)	Not specified

\*Patients were excluded if treated with RT or chemotherapy, but targeted therapy is not specified.

†CT scans acquired prior surgery; no information on prior treatments.

‡Mainly adenocarcinoma cases.

§Patients did receive target treatment, but no information on the administration of other treatments (immunotherapy and/or chemotherapy) is specified.

¶These studies provide age data as frequencies establishing an age threshold.

\*\*Inferred that NSCLC patients were included as it is specified that 17 patients had 19Del and 20 cases had L858R mutation; EGFR mutations are very rare in SCLC.

††In this study, there are 23 patients with no information about sex.

‡‡Image acquired 3 months before PCR; no information about treatments.

§§CT images acquired within 1 month before pathological diagnosis.


¶¶ Imaging-proven progression on first- or second-generation TKIs; patients underwent chest contrast-enhanced CT at the time of confirmed progression, and the interval between CT and confirmed progression was within 3 days.

---


ADC, adenocarcinoma; ALK, anaplastic lymphoma kinase; ASC, adenosquamous carcinoma; CT, computed tomography; EGFR, epidermal growth factor receptor; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; Freq. , frequency; KRAS, Kirsten rat sarcoma viral oncogene homologue; LCC, large cell lung carcinoma; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; PD-L1, programmed death ligand 1; PSC, pulmonary sarcomatoid carcinoma; RT, radiotherapy; SCC, Squamous cell carcinoma; SCLC, small-cell lung cancer; TKI , tyrosine kinase inhibitor; TP53, tumor suppressor protein 53.

## FIGURES

**Figure 1.** PRISMA flowchart. AI, artificial intelligence; CLAIM, Checklist for Artificial Intelligence in Medical Imaging; CT, computed tomography; MRI, magnetic resonance imaging.




**Figure 2.** Forest plots of the included studies developing radiomics models using machine learning and/or deep learning methods for the prediction of EGFR mutation status. Numbers are estimated with 95% CIs in brackets and indicated by horizontal lines. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally tag them as done in Tables 1 and 2 and in the reference list. EGFR, epidermal growth factor receptor; CI, confidence interval; DOR, diagnostic odds ratio; FPR, false




positive rate.

**Figure 3.** Forest plots of the included studies developing combined models (radiomics + clinical data) using machine learning and/or deep learning methods for the prediction of EGFR mutation status. Numbers are estimates with 95% CIs in brackets and indicated by horizontal lines. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally tag them as done in Tables 1 and 2 and in the reference list. EGFR, epidermal growth factor receptor; CI, confidence interval; DOR, diagnostic odds ratio;




**Figure 4.** Forest plots of the included studies developing radiomics models using machine learning and/or deep learning methods for the prediction of **A) ALK** and **B) KRAS** mutation status. Numbers are estimates with 95% CIs in brackets and indicated by horizontal lines. For those studies with the same name for the first author and published the same year, a hashtag was added to unequivocally tag them as done in Tables 1 and 2 and in the reference list. ALK, anaplastic lymphoma kinase; CI, confidence interval; DOR, diagnostic odds ration; FPR, false




positive rate; KRAS, Kirsten rat sarcoma viral oncogene homologue.

**Supplementary Figure S1.** Hierarchical sROC curves of included studies for the comparative performance of radiomics models and combined models (radiomics + clinical data) using machine learning and/or deep learning methods for the prediction of EGFR mutation status ( $n = 24$  and  $n = 23$  studies, respectively). EGFR, epidermal growth factor receptor.




**Supplementary Figure S2.** Hierarchical sROC curve of included studies for the performance of radiomics models for the prediction of ALK mutation status ( $n = 3$ ). ALK, anaplastic lymphoma kinase.





**Supplementary Figure S3.** Hierarchical sROC curve of included studies for the performance of radiomics models for the prediction of KRAS mutation status ( $n = 4$ ). KRAS, Kirsten rat sarcoma viral oncogene homologue.



## Supplementary tables

### Supplementary Table S1. Search strategy applied for the qualitative analysis (systematic review).

Databases	Search strategy
MEDLINE (via Pubmed)	("radiomics"[TIAB] OR "radiomic"[TIAB] OR "texture analysis"[TIAB]) AND ("lung neoplasms"[MESH] OR "lung cancer"[TIAB] OR "NSCLC"[TIAB] or "non-small cell lung cancer"[TIAB] OR "lung adenocarcinoma"[TIAB]) AND ("mutational status" OR "mutation" OR "molecular subtype" OR "ALK"[TIAB] OR "anaplastic lymphoma kinase"[TIAB] OR "BRAF"[TIAB] OR "EGFR"[TIAB] OR "Epidermal growth factor receptor"[TIAB] OR "ERRB2"[TIAB] OR "Receptor, ErbB-2"[MESH] OR "HER2"[TIAB] OR "KRAS"[TIAB] OR "Kirsten rat sarcoma virus"[TIAB] OR "Proto Oncogene Proteins c met"[TIAB] OR "NTRK"[TIAB] OR "ROS"[TIAB] OR "c-ros"[TIAB])
COCHRANE LIBRARY	("radiomics" OR "radiomic" OR "texture analysis") AND ("lung neoplasms" OR "lung cancer" OR "NSCLC" OR "non-small cell lung cancer") AND ("mutational status" OR "mutation" OR "molecular subtype" OR "ALK" OR "anaplastic lymphoma kinase" OR "BRAF" OR "EGFR" OR "ERRB2" OR "Receptor, ErbB-2" OR "HER2" OR "KRAS" OR "Kirsten rat sarcoma virus" OR "Proto Oncogene Proteins c met" OR "NTRK" OR "ROS" OR "c-ros")
EMBASE	('radiomics':ab,ti OR 'radiomics'/exp OR 'radiomic':ab,ti OR 'texture analysis':ab,ti) AND ('lung cancer'/exp OR 'lung cancer':ab,ti OR 'NSCLC'/exp OR 'NSCLC':ab,ti OR 'non small cell lung cancer'/exp OR 'non small cell lung cancer':ab,ti OR 'lung adenocarcinoma'/exp OR 'lung adenocarcinoma':ab,ti) AND

	<p>('mutational status':ab,ti OR ('mutational' NEAR/2 'status') OR 'mutation':ab,ti OR 'mutation'/exp OR 'molecular subtype':ab,ti OR ('molecular' NEAR/2 'subtype') OR 'ALK':ab,ti OR 'ALK gene'/exp OR 'anaplastic lymphoma kinase':ab,ti OR 'anaplastic lymphoma kinase'/exp OR 'BRAF':ab,ti OR 'BRAF gene'/exp OR 'EGFR':ab,ti OR 'EGFR gene'/exp OR 'Epidermal growth factor receptor':ab,ti OR 'Epidermal growth factor receptor gene'/exp OR 'ERRB2':ab,ti OR 'ERRB2 gene'/exp OR 'epidermal growth factor receptor 2'/exp OR 'epidermal growth factor receptor 2':ab,ti OR 'HER2':ab,ti OR 'KRAS':ab,ti OR 'KRAS gene'/exp OR 'Kirsten rat sarcoma virus':ab,ti OR 'Kirsten rat sarcoma virus'/exp OR 'Proto Oncogene Proteins c met' OR 'MET':ab,ti OR 'MET gene'/exp OR 'NTRK':ab,ti OR 'NTRK gene'/exp OR 'c ros oncogene 1':ab,ti OR 'ROS1':ab,ti OR 'ROS1 gene'/exp)</p>
--	---

**Supplementary Table S2.** Quality assessment results obtained after CLAIM evaluation.

<i>N</i>	Study	Score			Mean score	Cut-off
		Reviewer 1 (A.J.P.)	Reviewer 2 (F.B.B.)	Reviewer 3 (A.P.P.)		
1	Chang et al. 2021 <sup>1</sup>	28	24	27	26	17
2	Chang et al. 2021 <sup>2</sup>	26	25	26	26	17
3	Dong et al. 2021 <sup>3</sup>	23	22	19	21	18
4	Dong et al. 2022 <sup>4</sup>	25	22	21	23	18
5	Feng et al. 2022 <sup>5</sup>	20	22	23	22	18.5
6	Gao et al. 2023 <sup>6</sup>	22	22	20	21	17.5
7	Huo et al. 2022 <sup>7</sup>	22	25	25	24	17.5
8	Jia et al. 2019 <sup>8</sup>	19	19	20	19	17
9	Jiang et al. 2022 <sup>9</sup>	24	23	22	23	16.5
10	Le et al. 2021 <sup>10</sup>	22	20	21	21	17.5
11	Li et al. 2018 <sup>11</sup>	25	28	22	25	19
12	Li et al. 2019 <sup>12</sup>	23	22	21	22	17
13	Li et al. 2020 <sup>13</sup>	25	23	22	23	19
14	Li et al. 2022 <sup>14</sup>	21	21	21	21	17

15	Liu et al. 2020 <sup>15</sup>	22	25	23	23	17
16	Liu et al. 2022 <sup>16</sup>	24	23	22	23	17
17	Lu et al. 2020 <sup>17</sup>	27	30	26	28	17.5
18	Lu et al. 2022 <sup>18</sup>	22	25	21	23	17.5
19	Ma et al. 2020 <sup>19</sup>	24	26	22	24	17
20	Nair et al. 2021 <sup>20</sup>	21	22	19	21	17.5
21	Ninomiya et al. 2021 <sup>21</sup>	21	22	21	21	17.5
22	Ninomiya et al. 2023 <sup>22</sup>	21	22	22	22	17
23	Rios Velazquez et al. 2017 <sup>23</sup>	19	23	20	21	18
24	Rossi et al. 2021 <sup>24</sup>	20	22	19	20	17.5
25	Song et al. 2020 <sup>25</sup>	27	28	27	27	19
26	Tu et al. 2019 <sup>26</sup>	19	21	20	20	17
27	Wang et al. 2022 <sup>27</sup>	23	26	26	25	18
28	Wang et al. 2022 <sup>28</sup>	24	22	22	23	19
29	Weng et al. 2021 <sup>29</sup>	24	25	24	24	17.5
30	Wu 2020 <sup>30</sup>	20	22	21	21	17
31	Yang 2020 <sup>31</sup>	22	23	23	23	17
32	Yang 2022 <sup>32</sup>	19	18	18	18	17
33	Zhang 2018 <sup>33</sup>	26	27	23	25	17
34	Zhang 2020 <sup>34</sup>	19	19	19	19	17

35	Zhang 2020 <sup>35</sup>	22	23	23	23	17
36	Zhang 2021 <sup>36</sup>	27	26	26	26	17
37	Zhao 2022 <sup>37</sup>	23	24	23	23	19
38	Zhu 2022 <sup>38</sup>	22	22	20	21	17.5

**Supplementary Table S3.** Studies included in the different meta-analyses conducted.

N	EGFR		ALK	KRAS
	Radiomics models	Combined models	Radiomics models	Radiomics models
1	Chang et al. 2021 <sup>1</sup>	Dong et al. 2022 <sup>4</sup>	Chang et al. 2021 <sup>2</sup>	Dong et al. 2021 <sup>3</sup>
2	Dong et al. 2021 <sup>3</sup>	Gao et al. 2023 <sup>6</sup>	Ma et al. 2020 <sup>19</sup>	Le et al. 2021 <sup>10</sup>
3	Feng et al. 2022 <sup>5</sup>	Huo et al. 2022 <sup>7</sup>	Song et al. 2020 <sup>25</sup>	RiosVelazquez et al. 2017 <sup>23</sup>
4	Gao et al. 2023 <sup>6</sup>	Jia et al. 2019 <sup>8</sup>		Wang et al. 2022 <sup>28</sup>
5	Le et al. 2021 <sup>10</sup>	Jiang et al. 2022 <sup>9</sup>		
6	Li et al. 2018 <sup>11</sup>	Li et al. 2018 <sup>11</sup>		
7	Li et al. 2019 <sup>12</sup>	Li et al. 2019 <sup>12</sup>		
8	Li et al. 2022 <sup>14</sup>	Li et al. 2020 <sup>13</sup>		

9	Liu et al. 2020 <sup>15</sup>	Liu et al. 2020 <sup>15</sup>		
10	Liu et al. 2022 <sup>16</sup>	Lu et al. 2020 <sup>17</sup>		
11	Lu et al. 2020 <sup>17</sup>	Lu et al. 2022 <sup>18</sup>		
12	Lu et al. 2022 <sup>18</sup>	Ninomiya et al. 2023 <sup>22</sup>		
13	Nair et al. 2021 <sup>20</sup>	Rios Velazquez et al. 2017 <sup>23</sup>		
14	Ninomiya et al. 2021 <sup>21</sup>	Rossi et al. 2021 <sup>24</sup>		
15	RiosVelazquez et al. 2017 <sup>23</sup>	Tu et al. 2019 <sup>26</sup>		
16	Tu et al. 2019 <sup>26</sup>	Wang et al. 2022 <sup>27</sup>		
17	Wang et al. 2022 <sup>27</sup>	Weng et al. 2021 <sup>29</sup>		
18	Weng et al. 2021 <sup>29</sup>	Wu 2020 <sup>30</sup>		
19	Yang 2020 <sup>31</sup>	Yang 2022 <sup>32</sup>		
20	Zhang 2020 <sup>34</sup>	Zhang 2018 <sup>33</sup>		



21	Zhang 2020 <sup>35</sup>	Zhang 2020 <sup>35</sup>		
22	Zhang 2021 <sup>36</sup>	Zhang 2021 <sup>36</sup>		
23	Zhao 2022 <sup>37</sup>	Zhu 2022 <sup>38</sup>		
24	Zhu 2022 <sup>38</sup>			

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homologue.

**Supplementary Table S4.** Type of models (radiomic model/deep learning or combined [radiomic features + clinical variables]) developed in the studies for EGFR prediction and the radiomics/clinical features included. EGFR, epidermal growth factor receptor.

Study	Models	Radiomic features	Clinical variables
Chang et al. 2021 <sup>1</sup>	Radiomic	ShortRunLowGreyLevelEmphasis_AllDirection_offset1_SDH Percentile85 OneVoxelVolume Flatness ShortRunEmphasis_AllDirection_offset_SD HaralickCorrelation_AllDirection_offset4_SD Zone Percentage GLCM_Entropy_AllDirection_offset7_SD Correlation_AllDirection_offset7_SD CT_GLCMEntropy_AllDirection_offset1_SD HaralickCorrelation_angle135_offset7 LongRunHighGreyLevelEmphasis_angle0_offset ShortRunLowGreyLevelEmphasis_AllDirection_offset7_SD	N/A

		HaralickCorrelation_AllDirection_offset1_SD SurfaceVolumeRatio	
Dong et al. 2021 <sup>3</sup>	Deep learning	Not specified	N/A
Dong et al. 2022 <sup>4</sup>	Combined	wavelet-HLL_GLCM_MaximumProbability wavelet-LLL_GLCM_MaximumProbability original_GLCM_SumEntropy) log-sigma-1-0-mm-3D_GLCM_MaximumProbability wavelet-LHL_firstorder_Kurtosis wavelet-LLL_firstorder_Skewness log-sigma-2-0-mm-3D_firstorder_Kurtosis original_shape_Sphericity wavelet-LHL_GLSZM_LargeAreaHighG	Smoking status Histological type
Feng et al. 2022 <sup>5</sup>	Radiomic	Skewness.7_firstorder_wavelet-LHL SmallAreaHighGrayLevelEmphasis.7_GLSZM_wavelet-LHL HighGrayLevelZoneEmphasis.12_GLSZM_wavelet-HHH 90Percentile_firstorder_original Variance.4_firstorder_square Range.4_firstorder_square	

		<p>GrayLevelVariance.26_GLSZM_wavelet-LHH</p> <p>JointAverage.11_GLCM_wavelet-HLH</p> <p>MeanAbsoluteDeviation.4_firstorder_square RobustMeanAbsoluteDeviation.4_firstorder_square</p> <p>GrayLevelNonUniformity.32_GLSZM_wavelet-LLH   GrayLevelNonUniformity.1_girlm_original</p> <p>GrayLevelNonUniformity.4_girlm_logarithm GrayLevelNonUniformity.16_girlm_squareroot</p> <p>HighGrayLevelRunEmphasis.5_girlm_squareroot</p> <p>GrayLevelNonUniformityNormalized.21_GLSZM_wavelet-LLH LowGrayLevelRunEmphasis_girlm_original</p> <p>LowGrayLevelRunEmphasis.5_girlm_squareroot GrayLevelVariance.32_GLSZM_wavelet-LLH</p> <p>Minimum.4_firstorder_square SmallArealowGrayLevelEmphasis.11_GLSZM_wavelet-HLH</p> <p>SmallArealowGrayLevelEmphasis.12_GLSZM_wavelet-HHH</p> <p>Mean.12_firstorder_wavelet-HHH SmallArealowGrayLevelEmphasis.9_GLSZM_wavelet-HLL</p> <p>Imc2.12 GLCM wavelet-HHH</p> <p>ADC</p>	N/A
Gao et al. 2023 <sup>6</sup>	Radiomic Combined	<p>original_firstorder_Kurtosis</p> <p>original_firstorder_Median</p> <p>original_firstorder_Skewness</p> <p>log-sigma-1-0-mm-3D_firstorder_Energy</p>	<p>CEA</p> <p>Sex (male)</p> <p>Nodule type (sub-</p>

		<p>log-sigma-4-0-mm-3D_GLDM_DependenceVariance</p> <p>wavelet-LHL_GLRLM_LongRunLowGrayLevelEmphasis</p> <p>wavelet-HLL_firstorder_Energy</p>	solidity)
Huo et al. 2022 <sup>7*</sup>	Combined	137 features (not specified)	<p>Age</p> <p>Sex (female)</p> <p>Non-smokers</p> <p>Clinical stage (I-II)</p>
Jia et al. 2019 <sup>8</sup>	Combined	94 features (not specified)	<p>Sex</p> <p>Smoking history</p>
Jiang et al. 2022 <sup>9</sup>	Combined	<p>Skewness</p> <p>Minimum</p> <p>Kurtosis</p> <p>Variance</p> <p>Minimum</p> <p>10th percentile</p>	<p>Age</p> <p>Sex</p>

		<p>SumSquare</p> <p>SizeZoneNonUniformity</p> <p>HighGrayLevelZoneEmphasis</p> <p>ZoneVariance</p> <p>LargeDependence HighGrayLevelEmphasis</p> <p>LargeDependenceHighGrayLevel Emphasis</p> <p>DependenceEntropy</p>	<p>Smoking</p> <p>Tumor</p> <p>Family history</p>
Le et al. 2021 <sup>10</sup>	Radiomic	<p>wavelet-LLLfirstorderEnergy</p> <p>wavelet-LHHGLSZMGrayLevelNonUniformityNormalized</p> <p>wavelet-HHLGLDMSmallDependenceLowGratLevelEmphasis</p> <p>wavelet-HLHGLCM_MCC</p> <p>wavelet-HLHGLSZMSmallAreaLowGrayLevelEmphasis</p> <p>wavelet-HHHGLCMjointEnergy</p> <p>wavelet-HHHGLRLMGrayLevelNonUniformityNormalized</p>	N/A
Li et al. 2018 <sup>11</sup>	<p>Radiomic</p> <p>Combined</p>	338 features (not specified)	<p>Sex</p> <p>Smoking status</p>

Li et al. 2019 <sup>12</sup>	Radiomic Combined	CT_GGS_Gray Span CT_GGC_Gray Mean	Age Sex Smoking status Clinical stage Lesion location
Li et al. 2020 <sup>13</sup>	Combined	12 features (not specified)	Sex Age Smoking status
Li et al. 2022 <sup>14</sup>	Radiomic	3 features (not specified)	–
Liu et al. 2020 <sup>15</sup>	Radiomic Combined	<b>RADIOMIC MODEL:</b> wavelet-HLH_GLDM_DependenceVariance wavelet-LHL_GLDM_LargeDependenceLowGrayLevelEmphasis logarithm_GLCM_InverseVariance square_GLDM_DependenceVariance wavelet-HLH_GLDM_LargeDependenceHighGrayLevelEmphasis	

	<p>wavelet-HHH_GLCM_Id</p> <p>log-sigma-0-5-mm-3D_GLSZM_ZoneEntropy</p> <p>square_GLCM_Correlation</p> <p>original_GLCM_ClusterShade</p> <p>wavelet-LHH_GLDM_LargeDependenceHighGrayLevelEmphasis</p> <p><b>COMBINED MODEL:</b></p> <p>wavelet-HLH_GLDM_DependenceVariance</p> <p>custom_PatientSex</p> <p>logarithm_GLCM_InverseVariance</p> <p>square_GLCM_Correlation</p> <p>wavelet-HLL_firstorder_Kurtosis</p> <p>wavelet-LHL_GLRLM_LongRunLowGrayLevelEmphasis</p> <p>wavelet-HLL_firstorder_Median</p> <p>original_GLSZM_SizeZoneNonUniformityNormalized</p> <p>exponential_firstorder_Skewness</p>	<p>Age</p> <p>Sex</p> <p>Smoking history</p>
--	--	--



		wavelet-LLH_GLCM_ClusterShade	
Liu et al. 2022 <sup>16</sup>	Radiomic	Mean absolute deviation 60 Percentile area Convex Correlation Dissimilarity 5-1 Homogeneity 2 10-4 Homogeneity 2 -333-7 Information measure corr 1 8-1 Information measure corr 1 9-7 Information measure corr 1 2-4 Inverse diff norm 6-4 Inverse variance 8-4 Inverse variance 8-1 Max Probability 12-7 Max Probability	-

		-333 Run length nonuniformity	
Lu et al. 2020 <sup>17</sup>	Radiomic Combined	original_GLSZM_SmallAreaHighGrayLevelEmphasis original_GLSZM_SmallAreaLowGrayLevelEmphasis original_GLDM_LowGrayLevelEmphasis log-sigma-1-0-mm-3D_GLCM_Cluster Prominence log-sigma-3-0-mm-3D_GLDM_DependenceNonUniformityNormalized wavelet- LLL_GLCM_Inverse Variance wavelet-LLH_GLCM_Imc2 wavelet-HLL_firstorder_Mean wavelet-HLL_GLSZM_LowGrayLevelZoneEmphasis wavelet-HLL_GLDM_SmallDependenceHighGrayLevelEmphasis wavelet-HLH_GLSZM_SizeZoneNonUniformityNormalized wavelet-HHH_firstorder_Skewness wavelet-HHH_GLSZM_Size Zone Non Uniformity Normalized	Sex Smoking status Pathohistological subtype Vascular infiltration status
Lu et al. 2022 <sup>18</sup>	Radiomic Combined	1269 features (not specified)	Age Sex Smoking status Stage of disease

			Serum level of tumor markers (CEA, CYFRA 21-1, SCC, Pro-GRP)
Nair et al. 2021 <sup>20†</sup>	Radiomic	NGTDM_600_Complexity G1rl_Saggital_30_ShortRunEmphasis G1rl_Saggital_30_ShortRunHighGrayLevelEmphasis G1rl_Saggital_120_ShortRunHighGrayLevelEmphasis G1rl_Coronal_120_ShortRunHighGrayLevelEmphasis G1rl_Coronal_30_ShortRunEmphasis G1rl_Saggital_120_ShortRunEmphasis G1rl_Axial_30_ShortRunEmphasis G1rl_Coronal_120_ShortRunEmphasis FirstOrder_HistogramBin2	-
Ninomiya et al. 2021 <sup>21</sup>	Radiomic	<b>BN MODEL:</b> b0_GLCM_Energy_45, b1/b0_GLSZM_ZSN_104	

		<p>b1_GLCM_SumAverage_122</p> <p>b0_GLRLM_Lrlge_97)</p> <p><b>OI MODEL:</b></p> <p>GLRLM_ShortRunLowGrayLevelEmphasis</p> <p>GLSZM_LowGrayLevelZoneEmphasis</p> <p>GLSZM_ShortZoneLowGrayEmphasis</p> <p><b>WD MODEL:</b></p> <p>GLSZM_LowGrayLevelZoneEmphasis_LL</p>	-
Ninomiya et al. 2023 <sup>22</sup>	Combined	<p>GLSZM_SmallAreaLowGrayLevelEmphasis</p> <p>GLSZM_LargeAreaEmphasis</p> <p>Hist.RootMeanSquared</p> <p>GLDM_DependenceVariance</p>	Sex Smoking status
RiosVelazquez et al. 2017 <sup>23</sup>	Radiomic Combined	<p>imaging.Wavelet_LHH_GLCM_invDiffmomnor</p> <p>imaging.LoG_sigma_3_mm_3D_GLSZM_highIntensityLarteAreaEmp</p>	

		<p>imaging.Wavelet_LLL_GLCM_clusProm</p> <p>imaging.GLCM_maxProb</p> <p>imaging.Wavelet_LLL_stats_energy</p> <p>imaging.LoG_sigma_3_mm_3D_GLSZM_largeAreaEmphasis</p> <p>imaging.Wavelet_LHH_GLCM_clusProm</p> <p>imaging.Wavelet_LLL_GLSZM_highIntensityLarteAreaEmp</p> <p>imaging.Wavelet_HLH_GLSZM_lowIntensitySmallAreaEmp</p> <p>imaging.Wavelet_LLH_stats_mean</p> <p>imaging.Stats_median</p> <p>imaging.LoG_sigma_3_mm_3D_GLCM_clusProm</p> <p>imaging.Stats_kurtosis</p> <p>imaging.Wavelet_HHH_GLCM_correl1</p> <p>imaging.LoG_sigma_3_mm_3D_rlg1_grayLevelNonuniformity</p>	<p>imaging.Wavelet_HLL_stats_var</p> <p>imaging.Wavelet_LLH_stats_range</p> <p>imaging.Wavelet_HHL_stats_energy</p> <p>imaging.Wavelet_HHL_GLCM_maxProb</p> <p>imaging.Shape_spherDisprop</p>	<p>Stage</p> <p>Sex</p> <p>Smoking status</p> <p>Age</p> <p>Race</p>
Rossi et al. 2021 <sup>24</sup>	Combined	<p>First order_90 Percentile</p> <p>First order_Entropy</p> <p>First order_Maximum</p> <p>First order_Median</p> <p>First order_Robust mean absolute deviation</p>		<p>Sex</p> <p>Smoking status</p>

	<p>First order_Root mean squared</p> <p>First order_Skewness</p> <p>First order_Uniformity</p> <p>GLCM_Correlation</p> <p>GLCM_Difference average</p> <p>GLCM_Difference entropy</p> <p>GLCM_InverseDifference</p> <p>GLCM_InverseDifferenceMoment</p> <p>GLCM_InverseDifferenceMomentNormalized</p> <p>GLCM_InverseDifferenceNormalized</p> <p>GLCM_InformationalMeasureCorrelation1</p> <p>GLCM_InformationalMeasureCorrelation2</p> <p>GLCM_InverseVariance</p> <p>GLCM_JointEnergy</p> <p>GLCM_JointEntropy</p> <p>GLCM_MaximalCorrelationCoefficient</p>	
--	---	--

		GLCM_MaximumProbability GLCM_SumEntropy GLDM_DependenceEntropy GLDM_DependenceNonUniformity GLDM_Dependence NonUniformityNormalized GLDM_DependenceVariance GLDM_GrayLevelNonUniformity GLDM_LargeDependenceEmphasis GLDM_SmallDependenceEmphasis GLRLM_GrayLevelNonUniformity GLRLM_GrayLevelNonUniformityNormalized GLRLM_RunEntropy GLRLM_RunPercentage GLRLM_ShortRunEmphasis GLSZM_GrayLevelNonUniformity GLSZM_GrayLevelNonUniformityNormalized	
--	--	--	--

		<p>GLSZM_SizeZoneNonUniformityNormalized</p> <p>GLSZM_SmallAreaEmphasis</p> <p>GLSZM_ZoneEntropy</p> <p>GLSZM_ZoneVariance</p> <p>NGTDM_Coarseness</p>	
Tu et al. 2019 <sup>26</sup>	<p>Radiomic</p> <p>Combined</p>	<p>X0_GLRLM_RunLengthNon-Uniformity</p> <p>X4_H_median</p> <p>X0_GLCM_homogeneity1</p>	<p>Maximum diameter</p> <p>Location</p> <p>Sex</p>
Wang et al. 2022 <sup>27</sup>	<p>Radiomic</p> <p>Combined<sup>‡</sup></p>	Not specified	<p>Age</p> <p>Sex</p> <p>Tumor staging</p> <p>Number</p> <p>Size</p> <p>Past recurrence</p> <p>Medication status</p>



Weng et al. 2021 <sup>29</sup>	Combined	<p>SmallAreaEmphasis</p> <p>LongRunHigh GreyLevelEmphasis_angle0_offset4</p> <p>ClusterProminence_All Direction_offset7_SD</p> <p>InverseDifference Moment_All Direction_offset4_SD</p> <p>LowGreyLevel Run Emphasis_All Direction_offset4_SD</p> <p>LongRunLowGrey Level Emphasis_All Direction_offset7_SDCorrelation_angle0_offset7</p> <p>std Deviation</p> <p>GLCM Energy_All Direction_offset4_SD</p>	<p>Smoking status</p> <p>Spiculation</p> <p>Air bronchogram</p> <p>CEA</p> <p>SCCA</p>
Wu 2020 <sup>30</sup>	Combined	Not specified	<p>Smoking status</p> <p>Histological subtype</p>
Yang 2020 <sup>31</sup>	Radiomic	Not specified	-
Yang 2022 <sup>32</sup>	<p>Radiomic</p> <p>Combined</p>	<p>Nonwavelet-LHH_NGTDMM_Strength</p> <p>wavelet-LHH_GLDM_DependenceEntropy</p> <p>wavelet-LLL_GLSZM_LargeAreaLowGrayLevelEmphasis</p> <p>wavelet-LLL_firstorder_Minimum</p>	<p>Sex</p> <p>Emphysema</p> <p>Interstitial lung disease</p>

		<p>wavelet-LLH_NGTDM_Contrast</p> <p>wavelet-LHH_NGTDM_Strength</p> <p>log-sigma-1-5-mm-3D_firstorder_Kurtosis</p> <p>wavelet-LHL_GLCM_ClusterShade</p> <p>wavelet-LHH_NGTDM_Strength</p> <p>wavelet-LLL_GLSZM_LargeAreaLowGrayLevelEmphasis</p> <p>wavelet-LLH_firstorder_Mean</p> <p>original_NGTDM_Contrast</p> <p>original_firstorder_Kurtosis</p> <p>log-sigma-1-5-mm-3D_firstorder_Kurtosis</p> <p>wavelet-LLL_NGTDM_Contrast</p> <p>original_GLCM_MaximumProbability</p> <p>wavelet-LLL_GLSZM_LargeAreaLowGrayLevelEmphasis</p>	
Zhang 2018 <sup>33</sup>	Combined	<p>IIF.range</p> <p>IIF.Skewness</p> <p><math>W_{LLH}F.IF.mean\_absolute\_eviation</math></p>	<p>Histological subtype</p> <p>Sex</p> <p>Smoking status</p>

		$W_{LHHF}.IF.median$ $W_{LLHF}.IF.mean$ $W_{LLHF}.GLCM.variance$ GLRLM_HighGrayLevelRunEmphasis	
Zhang 2020 <sup>34</sup>	Radiomic	GLSZM_HighGrayLevelZoneEmphasis GLDM_DependenceVariance GLSZM_GreyLevelNon UniformityNormalized GLSZM_ZoneEntropy	-
Zhang 2020 <sup>35</sup>	Radiomic Combined	784 features (not specified)	Sex Histopathological Subtype Age
Zhang 2021 <sup>36</sup>	Radiomic Combined	fo_Skewness exp_GLRLM_ShortRunEmphasis exp_GLRLM_ShortRunHighGrayLevelEmphasis exp_GLDM_SmallDependenceEmphasis	Smoking history Bubble-like lucency Pleural attachment Pleural retraction

		<p>grad_GLDM_DependenceEntropy</p> <p>LLH_fo_90P</p> <p>LLH_GLCM_SumEntropy</p> <p>LLL-fo_kurtosis</p> <p>LLL-GLCM_ClusterProminence</p> <p>LLL_GLSZM_GrayLevelNonUniformityNormalized</p> <p>LLL_GLSZM_GrayLevelVariance</p> <p>LLL_GLSZM_ZoneEntropy</p>	
Zhao 2022 <sup>37§</sup>	Radiomic	<p>CT_Shape_Sphericity</p> <p>CT_GLRLM_ShortRunEmphasis</p> <p>CT_GLRLM_ShortRunHighGreyLevelEmphasis</p> <p>CT_NGLDM_Busyness</p> <p>CT_Glzlm_ShortZoneEmphasis</p>	-
Zhu 2022 <sup>38</sup>	<p>Radiomic</p> <p>Combined</p>	<p>log_sigma_1.0_mm_3D_GLRLM_RunVariance</p> <p>wavelet_LLH_firstorder_RootMeanSquared</p> <p>log-sigma-2-0-mm-3D_GLCM_ClusterShade</p>	<p>Sex</p> <p>Age</p> <p>Emphysema</p>

	wavelet_HHH_firstorder_Mean	Pathological subtype
--	-----------------------------	----------------------

\*Combined model also included 14 CT features: location (peripheral), tumor size  $\geq 3$ cm, subsolid density, spiculation, lobulation, air bronchogram, air space, necrosis, calcification (presence), vascular convergence sign, pleural retraction sign, pleural effusion, lymphatic metastasis and multiple pulmonary metastasis.

†Top 10 selected features. The maximum number of texture features included was determined by maximizing cross-validated accuracy. This value was not the same for each binary group or each machine learning model.

‡Note that this model includes radiomic features + deep features and clinical variables.

§Model 1.

BN, Betti numbers; CEA, carcinoembryonic antigen; CYFRA 21-1, fragment of cytokeratin sub-unit 19; GLCM, gray-level co-occurrence matrix; GLDM, gray-level dependence matrix; GLRLM, gray-level run-length matrix; GLSZM, gray-level size zone matrix; NGTDM, neighbouring gray tone difference matrix; OI, original image; Pro-GRP, pro-gastrin-releasing peptide; SCC, squamous cell carcinoma antigen; WD, wavelet decomposition.

**Supplementary Table S5.** Type of models (radiomic model or combined [radiomic features + clinical variables]) developed in the studies for ALK prediction and the radiomics/clinical features included. ALK, anaplastic lymphoma kinase.

Study	Models	Radiomic features	Clinical variables
Chang et al. 2021 <sup>2</sup>	Radiomic	CT_uniformity CT_LongRunEmphasis_AllDirection_offset4_SD CT_HaraEntropy CT_GLCMEnergy_angle135_offset7 CT_LongRunHighGreyLevelEmphasis_angle45_offset1 CT_LongRunLowGreyLevelEmphasis_AllDirection_offset7_SD CT_Correlation_AllDirection_offset4_SD CT_Percentile70 CT_HaralickCorreltion_AllDirection_offset4_SD CT_LongRunLowGreyLevelEmphasis_AllDirection_offset4_SD CT_LongRunEmphasis_angle135_offset4 CT_LongRunHighGreyLevelEmphasis_angle90_offset4	-

		<p>CT_LongRunLowGreyLevelEmphasis_AllDirection_offset1_SD</p> <p>CT_HaralickCorreltion_AllDirection_offset7_SD</p> <p>CT_ShortRunEmphasis_AllDirection_offset1_SD</p> <p>CT_LongRunHighGreyLevelEmphasis_angle0_offset1</p> <p>CT_GLCMEntropy_angle90_offset1</p> <p>CT_Percentile30</p> <p>CT_LongRunEmphasis_angle90_offset4</p> <p>CT_LongRunEmphasis_AllDirection_offset1_SD</p>	
Ma et al. 2020 <sup>19</sup>	Radiomic	<p><b>PRE-CONTRAST MODEL:</b></p> <p>wavelet-LLL_GLCM_DifferenceVariance</p> <p>wavelet-LLH_firstorder_Median</p> <p>wavelet-LLH_NGTDN_Busyness</p> <p>wavelet-LHL_GLSZM_LargeAreaLowGrayLevelEmphasis</p> <p>wavelet-HHH_GLSZM_LargeAreaLowGrayLevelEmphasis</p> <p>wavelet-LHL_firstorder_Energy</p>	-

		<p>wavelet-HHL_firstorder_90Percentile</p> <p>wavelet-HHL_GLCM_JointEntropy</p> <p>wavelet-HHL_firstorder_Uniformity</p> <p>wavelet-HHL_firstorder_RobustMeanAbsoluteDeviation</p> <p>wavelet-LHH_GLDM_LargeDependenceLowGrayLevelEmphasis</p> <p>wavelet-HLH_firstorder_Median</p> <p>wavelet-LHL_GLDM_LargeDependenceLowGrayLevelEmphasis</p> <p>wavelet-HHL_GLCM_InverseDifference</p> <p>wavelet-HHL_firstorder_InterquartileRange</p> <p>wavelet-HHL_GLCM_MaximumProbabibility</p> <p>wavelet-HHH_GLSZM_SmallAreaLowGrayLevelEmphasis</p> <p>wavelet-HHL_firstorder_Mean</p> <p>wavelet-HLL_GLCM_ClusterShade</p> <p>wavelet-HHL_GLSZM_SmallAreaLowGrayLevelEmphasis</p> <p>wavelet-LHH_GLCM_MaximalCorrelationCoefficient</p> <p>wavelet-LLL_GLSZM_SizeZoneNonUniformityNormalized</p>	
--	--	--	--



		<p>wavelet-LLL_GLSZM_SmallAreaEmphasis</p> <p>wavelet-HHL_GLCM_InverseDifferenceNormalized</p> <p><b>POST-CONTRAST MODEL:</b></p> <p>wavelet-LHH_GLDM_SmallDependenceHighGrayLevelEmphasis</p> <p>wavelet_HHL_GLSZM_GrayLevelNonUniformity</p> <p>wavelet-LLH_firstorder_Mean</p> <p>wavelet-LLH_GLSZM_HighGrayLevelZoneEmphasis</p> <p>wavelet-LLH_GLSZM_SmallAreaHighGrayLevelEmphasis</p> <p>wavelet-LLH_GLSZM_SmallAreaLowGrayLevelEmphasis</p> <p>wavelet-HHH_GLCM_MaximumProbability</p> <p>wavelet-LLL_GLDM_LargeDependenceLowGrayLevelEmphasis</p> <p>wavelet-HLL_GLDM_DependenceVariance</p> <p>wavelet-HHH_firstorder_Mean</p> <p>wavelet-HHH_GLDM_LowGrayLevelEmphasis</p> <p>wavelet-LLH_firstorder_90Percentile</p>	
--	--	--	--

		<p>wavelet-HHL_GLDM_DependenceVariance</p> <p>wavelet-HHH_GLCM_MaximalCorrelationCoefficient</p> <p>wavelet-HHH_NGTDm_Contrast</p> <p>wavelet-original_GLCM_InverseVariance</p> <p>wavelet-LLH_firstorder_Range</p> <p>wavelet-HHL_GLCM_MaximalCorrelationCoefficient</p> <p>wavelet-HLL_GLSZM_GrayLevelNonUniformityNormalized</p>	
<p>Song et al. 2020<sup>25</sup></p>	<p>Radiomic Combined</p>	<p><b>RADIOMIC MODEL:</b></p> <p>Original_Firstorder_90Percentile</p> <p>Original_Firstorder_Entropy</p> <p>Original_Firstorder_Maximum</p> <p>Wavelet-LHH_Firstorder_10Percentile</p> <p>Wavelet-HLL_Firstorder_Median</p> <p>Wavelet-HHH_Firstorder_Mean</p> <p>LoG-sigma-1-0-mm-3D_Firstorder_Median</p>	<p>Age</p> <p>Sex</p> <p>Smoking history</p>

	<p>LoG-sigma-1-0-mm-3D_Firstorder_RootMeanSquared</p> <p>LoG-sigma-1-0-mm-3D_Firstorder_Minimum</p> <p>LoG-sigma-2-0-mm-3D_Firstorder_10Percentile</p> <p>LoG-sigma-3-0-mm-3D_Firstorder_90Percentile</p> <p>LoG-sigma-5-0-mm-3D_Firstorder_Skewness</p> <p>Original_GLCM_ClusterShade</p> <p>Wavelet-LHH_GLCM_Correlation</p> <p>Wavelet-LHL_GLCM_InverseDifferenceNormalized</p> <p>Wavelet-HHH_GLCM_InformationalMeasureofCorrelation1</p> <p>LoG-sigma-1-0-mm-3D_GLCM_Autocorrelation</p> <p>LoG-sigma-2-0-mm-3D_GLCM_InverseVariance</p> <p>Original_GLSZM_SmallAreaHighGrayLevelEmphasis</p> <p>Wavelet-HHH_GLSZM_SmallAreaHighGrayLevelEmphasis</p> <p>Wavelet-HLL_GLSZM_ZoneEntropy</p> <p>Wavelet-HLH_GLSZM_ZoneEntropy</p> <p>LoG-sigma-2-0-mm-3D_GLSZM_ZoneEntropy</p>	<p>Smoking index</p> <p>Clinical stage Distal metastasis</p> <p>Pathological invasiveness of the tumor</p>
--	---	--

	<p>LoG-sigma-3-0-mm-3D_GLSZM _ SmallAreaEmphasis</p> <p>LoG-sigma-3-0-mm-3D_GLSZM _ Size-ZoneNonUniformityNormalized</p> <p>LoG-sigma-5-0-mm-3D_GLSZM _ GrayLevelNonUniformityNormalized</p> <p>Wavelet-LHH_GLDM_ LargeDependenceHighGrayLevelEmphasis</p> <p>LoG-sigma-1-0-mm-3D_GLDM _ HighGrayLevelEmphasis</p> <p>LoG-sigma-3-0-mm-3D_GLRLM_RunPercentage</p> <p>LoG-sigma-4-0-mm-3D_GLRLM _ LongRunLowGrayLevelEmphasis</p> <p><b>COMBINED MODEL:</b></p> <p>Current smoker</p> <p>Stage I</p> <p>Male</p> <p>Local lymphadenopathy</p> <p>Pericardial effusion</p> <p>Left Lower Lobe lesion</p> <p>No cavity in the lesion</p>	
--	---	--

		<p>Lobulated margin</p> <p>No pleural retraction sign</p> <p>No local lymphadenopathy</p> <p>Wavelet-HHL_Firstorder_Kurtosis</p> <p>Wavelet-HLL_Firstorder_Median</p> <p>Wavelet-LHH_Firstorder_Skewness</p> <p>Wavelet-LLL_Firstorder_Minimum</p> <p>Wavelet-HLH_Firstorder_Median</p> <p>LoG-sigma-1-0-mm-3D_Firstorder_Minimum</p> <p>LoG-sigma-2-0-mm-3D_Firstorder_Minimum</p> <p>Wavelet-LLL_GLCM_ClusterShade</p> <p>Wavelet-LLH_GLCM _InformationalMeasureofCorrelation2</p> <p>Wavelet-HLH_GLCM _InformationalMeasureofCorrelation2</p> <p>Wavelet-HLH_GLCM _InformationalMeasureofCorrelation1</p> <p>LoG-sigma-1-0-mm-3D_GLCM _InformationalMeasureofCorrelation1</p> <p>LoG-sigma-3-0-mm-3D_GLCM _InformationalMeasureofCorrelation2</p>	
--	--	--	--

		LoG-sigma-5-0-mm-3D_GLCM_InformationalMeasureofCorrelation2 Original_Shape_MajorAxisLength Wavelet-HLH_GLSZM_SizeZoneNon-Uniformity LoG-sigma-4-0-mm-3D_GLSZM_GrayLevelNonUniformityNormalized Wavelet-HLH_GLDM_ LargeDependenceHigh GrayLevelEmphasis Wavelet-HHH_GLDM_ LargeDependenceHigh GrayLevelEmphasis Original_GLRLM_ HighGrayLevelRunEmphasis	
--	--	---	--

GLCM , gray-level co-occurrence matrix; GLDM , gray-level dependence matrix; GLRLM , gray-level run-length matrix; GLSZM , gray-level size zone matrix; NGTDM , neighbouring gray tone difference matrix.

**Supplementary Table S6.** Type of models (radiomic model or combined [radiomic features + clinical variables]) developed in the studies for KRAS prediction and the radiomics/clinical features included. KRAS, Kirsten rat sarcoma viral oncogene homologue.

Study	Models	Radiomic features	Clinical variables
Dong et al. 2021 <sup>3</sup>	Radiomic	Not specified	-
Le et al. 2021 <sup>10</sup>	Radiomic	wavelet-LLHGLSZMLargeAreaEmphasis wavelet-LLLGLDMDependenceEntropy wavelet-LHHGLDMLargeDependenceLowGrayLevelEmphasis ori-firstorderkurtosis wavelet-HLHGLCMInverseVariance wavelet-HLLGLSZMSmallAreaHighGrayLevelEmphasis wavelet-LHHGLCMId wavelet-HHLGLCMDifferenceEntropy	-

		<p>wavelet-LLLGLSZMGrayLevelNonUniformityNormalized</p> <p>wavelet-HHHGLCMDifferenceAverage</p> <p>wavelet-HHHGLDMDependenceEntropy</p>	
RiosVelazquez et al. 2017 <sup>23</sup>	<p>Radiomic</p> <p>Combined</p>	<p>imaging.LoG_sigma_3_mm_3D_GLSZM_highIntensityLarteAreaEmp</p> <p>imaging.Wavelet_LHH_GLCM_clusProm                      imaging.Wavelet_LHH_GLCM_energy</p> <p>imaging.Wavelet_LLL_stats_energy                      imaging.Wavelet_LLL_stats_median</p> <p>imaging.LoG_sigma_3_mm_3D_GLSZM_largeAreaEmphasis</p> <p>imaging.Wavelet_HHH_GLSZM_lowIntensitySmallAreaEmp</p> <p>imaging.Wavelet_HHH_GLCM_correl1              imaging.LoG_sigma_3_mm_3D_GLCM_clusProm</p> <p>imaging.Wavelet_LLL_GLSZM_highIntensityLarteAreaEmp    imaging.Wavelet_HHL_stats_energy</p> <p>imaging.Wavelet_HLL_stats_var      imaging.Wavelet_HLH_GLSZM_lowIntensitySmallAreaEmp</p> <p>imaging.Wavelet_LHH_rlgl_GrayLevelNonuniformity</p> <p>imaging.LoG_sigma_3_mm_3D_GLSZM_lowIntensitySmallAreaEmp    imaging.GLCM_clusShade</p> <p>imaging.Wavelet_LHH_GLCM_invDiffmomnor                      imaging.Wavelet_HLL_stats_min</p> <p>imaging.Wavelet_LLL_rlgl_longRunHighGrayLevEmpha    imaging.Wavelet_LLH_stats_mean</p>	<p>Stage</p> <p>Sex</p> <p>Smoking status</p> <p>Age</p> <p>Race</p>
Wang et al. 2022 <sup>28</sup>	Radiomic	<p>CT_square_GLSZM_SizeZoneNonUniformityNormalized</p> <p>CT_wavelet-LHH_GLDM_DependenceNonUniformityNormalized</p>	-



		CT_wavelet-HHL_firstorder_Skewness	
		CT_wavelet-HHL_GLDM_DependenceNonUniformityNormalized	

GLCM , gray-level co-occurrence matrix; GLDM , gray-level dependence matrix; GLRLM , gray-level run-length matrix; GLSZM , gray-level size zone matrix.

**Supplementary Table S7.** Results of the meta-regression analyzing the effects of age, type of segmentation (manual/semi-automatic/automatic), type of model (radiomics/combined [radiomic features + clinical data] and artificial intelligence methodology (machine learning/deep learning).

<b>AGE</b>					
Fixed-effects coefficients					
	<b>Estimate</b>	<b>SE</b>	<b>z</b>	<b>p-value</b>	<b>CI 95%</b>
tsens.(Intercept)	4.488	2.181	2.058	0.040	[0.214, 8.762]
tsens.AGE	-0.052	0.035	-1.483	0.138	[-0.121, 0.017]
tfpr.(Intercept)	-0.156	2.288	-0.068	0.946	[-4.640, 4.328]
tfpr.AGE	-0.012	0.037	-0.318	0.750	[-0.084, 0.061]
Variance components: between-studies Std. Dev and correlation matrix					
	<b>SD</b>			<b>tsens</b>	<b>tfpr</b>
tsens	0.395			-	0.819
tfpr	0.431			0.819	-
<b>TYPE OF SEGMENTATION</b>					
Fixed-effects coefficients					
	<b>Estimate</b>	<b>SE</b>	<b>z</b>	<b>p-value</b>	<b>CI 95%</b>
tsens.(Intercept)	1.217	0.127	9.599	0.000	[0.968, 1.465]
tsens.SegmentationSemiautomatic	-0.086	0.241	-0.356	0.722	[-0.558, 0.387]

tsens.SegmentationUnknown	0.347	0.708	0.491	0.624	[-1.040, 1.734]
tfpr.(Intercept)	-0.984	0.133	-7.426	0.000	[-1.244, -0.725]
tfpr.SegmentationSemiautomatic	0.272	0.254	1.067	0.286	[-0.227, 0.770]
tfpr.SegmentationUnknown	0.397	0.697	0.569	0.569	[-0.970, 1.763]
Variance components: between-studies Std. Dev and correlation matrix					
	<b>SD</b>		<b>tsens</b>		<b>tfpr</b>
tsens	0.465		-		0.827
tfpr	0.511		0.827		-
<b>CONTRAST</b>					
Fixed-effects coefficients					
	<b>Estimate</b>	<b>SE</b>	<b>z</b>	<b>p-value</b>	<b>CI 95%</b>
tsens.(Intercept)	1.244	0.608	2.045	0.041	[0.052, 2.437]
tsens.Contrastcontrast-enhanced	0.151	0.650	0.232	0.817	[-1.124, 1.425]
tsens.Contrastnon-contrast CT	-0.096	0.620	-0.156	0.876	[-1.312, 1.119]
tfpr.(Intercept)	-0.619	0.638	-0.970	0.332	[-1.870, 0.632]
tfpr.Contrastcontrast-enhanced	-0.509	0.683	-0.745	0.456	[-1.848, 0.829]
tfpr.Contrastnon-contrast CT	-0.309	0.650	-0.476	0.634	[-1.584, 0.965]
Variance components: between-studies Std. Dev and correlation matrix					

	<b>SD</b>	<b>tsens</b>	<b>tfpr</b>		
tsens	0.468	-	0.889		
tfpr	0.511	0.889	-		
<b>TYPE OF MODEL</b>					
Fixed-effects coefficients					
	<b>Estimate</b>	<b>SE</b>	<b>z</b>	<b>p-value</b>	<b>CI 95%</b>
tsens.(Intercept)	1.281	0.133	9.603	0.000	[1.020, 1.543]
tsens.Modelrad	-0.193	0.197	-0.980	0.327	[-0.579, 0.193]
tfpr.(Intercept)	-0.939	0.146	-6.413	0.000	[-1.226, -0.652]
tfpr.Modelrad	0.006	0.222	0.026	0.979	[-0.429, 0.441]
Variance components: between-studies Std. Dev and correlation matrix					
	<b>SD</b>	<b>tsens</b>	<b>tfpr</b>		
tsens	0.434	-	0.828		
tfpr	0.524	0.828	-		
<b>AI METHODOLOGY</b>					
Fixed-effects coefficients					
	<b>Estimate</b>	<b>SE</b>	<b>z</b>	<b>p-value</b>	<b>CI 95%</b>
tsens.(Intercept)	1.215	0.232	5.2240	0.000	[0.761, 1.670]
tsens.TypeML	-0.022	0.257	-0.087	0.930	[-0.526, 0.481]

tfpr.(Intercept)	-0.898	0.257	-3.489	0.000	[-1.403, 0.394]
tfpr.TypeML	-0.052	0.285	-0.184	0.854	[-0.610, 0.505]
Variance components: between-studies Std. Dev and correlation matrix					
	<b>SD</b>	<b>tsens</b>	<b>tfpr</b>		
tsens	0.442	-	0.795		
tfpr	0.520	0.795	-		

AI, artificial intelligence; CI, confidence interval; ML, machine learning; rad, model including only radiomic features; SE, standard error; SD, Standard deviation; z, standard score in a gaussian distribution; tsens, logarithmic transformation of sensitivity; tfpr, logarithmic transformation of false positive rate.

## REFERENCES

- 1 Chang C, Zhou S, Yu H et al. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma. *Eur Radiol*. 2021; 31(8): 6259-6268.
- 2 Chang C, Sun X, Wang G et al. A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. *Front Oncol*. 2021; 11: 603882.
- 3 Dong Y, Hou L, Yang W et al. Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images. *Quant Imaging Med Surg*. 2021; 11(6): 2354-2375.
- 4 Dong Y, Jiang Z, Li C et al. Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer. *Quant Imaging Med Surg*. 2022; 12(5): 2658-2671.
- 5 Feng Y, Song F, Zhang P et al. Prediction of EGFR mutation status in non-small cell lung cancer based on ensemble learning. *Front Pharmacol*. 2022; 13: 897597.
- 6 Gao J, Niu R, Shi Y et al. The predictive value of [(18)F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma. *EJNMMI Res*. 2023; 13(1): 26.
- 7 Huo JW, Luo TY, Diao L et al. Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma. *Front Oncol*. 2022; 12: 846589.
- 8 Jia TY, Xiong JF, Li XY et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. *Eur Radiol*. 2019; 29(9): 4742-4750.
- 9 Jiang M, Yang P, Li J et al. Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and

- efficacy of first-line targeted therapy in lung adenocarcinoma. *Front Oncol.* 2022; 12: 985284.
- 10 Le NQK, Kha QH, Nguyen VH et al. Machine learning-based radiomics signatures for EGFR and KRAS mutations prediction in non-small-cell lung cancer. *Int J Mol Sci.* 2021; 22(17).
  - 11 Li XY, Xiong JF, Jia TY et al. Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks. *J Thorac Dis.* 2018; 10(12): 6624-6635.
  - 12 Li X, Yin G, Zhang Y et al. Predictive power of a radiomic signature based on (18)F-FDG PET/CT images for EGFR mutational status in NSCLC. *Front Oncol.* 2019; 9: 1062.
  - 13 Li S, Luo T, Ding C et al. Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning. *Med Phys.* 2020; 47(8): 3458-3466.
  - 14 Li S, Li Y, Zhao M et al. Combination of (18)F-fluorodeoxyglucose PET/CT radiomics and clinical features for predicting epidermal growth factor receptor mutations in lung adenocarcinoma. *Korean J Radiol.* 2022; 23(9): 921-930.
  - 15 Liu G, Xu Z, Ge Y et al. 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma. *Transl Lung Cancer Res.* 2020; 9(4): 1212-1224.
  - 16 Liu Y, Zhou J, Wu J et al. Development and validation of machine learning models to predict epidermal growth factor receptor mutation in non-small cell lung cancer: a multi-center retrospective radiomics study. *Cancer Control.* 2022; 29: 10732748221092926.
  - 17 Lu X, Li M, Zhang H et al. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma. *Phys Med Biol.* 2020; 65(5): 055012.

- 18 Lu J, Ji X, Wang L et al. Machine learning-based radiomics for prediction of epidermal growth factor receptor mutations in lung adenocarcinoma. *Dis Markers*. 2022; 2022: 2056837.
- 19 Ma DN, Gao XY, Dan YB et al. Evaluating solid lung adenocarcinoma anaplastic lymphoma kinase gene rearrangement using noninvasive radiomics biomarkers. *Onco Targets Ther*. 2020; 13: 6927-6935.
- 20 Nair JKR, Saeed UA, McDougall CC et al. Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer. *Can Assoc Radiol J*. 2021; 72(1): 109-119.
- 21 Ninomiya K, Arimura H, Chan WY et al. Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers. *PLoS One*. 2021; 16(1): e0244354.
- 22 Ninomiya K, Arimura H, Tanaka K et al. Three-dimensional topological radiogenomics of epidermal growth factor receptor Del19 and L858R mutation subtypes on computed tomography images of lung cancer patients. *Comput Methods Programs Biomed*. 2023; 236: 107544.
- 23 Rios Velazquez E, Parmar C, Liu Y et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. *Cancer Res*. 2017; 77(14): 3922-3930.
- 24 Rossi G, Barabino E, Fedeli A et al. Radiomic detection of EGFR mutations in NSCLC. *Cancer Res*. 2021; 81(3): 724-731.
- 25 Song L, Zhu Z, Mao L et al. Clinical, conventional ct and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients. *Front Oncol*. 2020; 10: 369.
- 26 Tu W, Sun G, Fan L et al. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. *Lung Cancer*. 2019; 132: 28-35.
- 27 Wang C, Ma J, Shao J et al. Predicting EGFR and PD-L1 status in NSCLC patients using multitask ai system based on CT images. *Front Immunol*. 2022; 13: 813072.



- 28 Wang J, Lv X, Huang W et al. Establishment and optimization of radiomics algorithms for prediction of KRAS gene mutation by integration of NSCLC gene mutation mutual exclusion information. *Front Pharmacol.* 2022; 13: 862581.
- 29 Weng Q, Hui J, Wang H et al. Radiomic feature-based nomogram: a novel technique to predict EGFR-activating mutations for EGFR tyrosin kinase inhibitor therapy. *Front Oncol.* 2021; 11: 590937.
- 30 Wu S, Shen G, Mao J et al. CT radiomics in predicting EGFR mutation in non-small cell lung cancer: a single institutional study. *Front Oncol.* 2020; 10: 542957.
- 31 Yang C, Chen W, Gong G et al. Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma. *Transl Cancer Res.* 2020; 9(11): 6683-6690.
- 32 Yang X, Liu M, Ren Y et al. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis. *Eur Radiol.* 2022; 32(4): 2693-2703.
- 33 Zhang L, Chen B, Liu X et al. Quantitative biomarkers for prediction of epidermal growth factor receptor mutation in non-small cell lung cancer. *Transl Oncol.* 2018; 11(1): 94-101.
- 34 Zhang M, Bao Y, Rui W et al. Performance of (18)F-FDG PET/CT radiomics for predicting EGFR mutation status in patients with non-small cell lung cancer. *Front Oncol.* 2020; 10: 568857.
- 35 Zhang B, Qi S, Pan X et al. Deep CNN model using CT radiomics feature mapping recognizes EGFR gene mutation status of lung adenocarcinoma. *Front Oncol.* 2020; 10: 598721.
- 36 Zhang G, Cao Y, Zhang J et al. Predicting EGFR mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. *Am J Cancer Res.* 2021; 11(2): 546-560.

- 37 Zhao HY, Su YX, Zhang LH et al. Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma. *Neoplasma*. 2022; 69(1): 233-241.
- 38 Zhu H, Song Y, Huang Z et al. Accurate prediction of epidermal growth factor receptor mutation status in early-stage lung adenocarcinoma, using radiomics and clinical features. *Asia Pac J Clin Oncol*. 2022; 18(6): 586-594.